

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00, A01K 67/027, C12N 15/86, 9/72		A1	(11) International Publication Number: WO 99/43795
			(43) International Publication Date: 2 September 1999 (02.09.99)
(21) International Application Number: PCT/CA98/00607		(74) Agents: ERRATT, Judy, A. et al.; Gowling, Strathy & Henderson, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3 (CA).	
(22) International Filing Date: 25 June 1998 (25.06.98)			
(30) Priority Data: 2,224,108 24 February 1998 (24.02.98) CA		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): HER MAJESTY IN RIGHT OF CANADA as represented by THE MINISTER OF AGRICULTURE AND AGRI-FOOD CANADA [CA/CA]; Building 34, Centre for Food and Animal Research, Central Experimental Farm, Ottawa, Ontario K1A 0C6 (CA).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): GAVORA, Jan, S. [CA/CA]; 51 Forest Hill Avenue, Ottawa, Ontario K2C 1P7 (CA). FALCONER, Marcia, M. [CA/CA]; 33 Abingdon Drive, Nepean, Ontario K2H 7M5 (CA). NGUYEN, Thuy, H. [CA/CA]; Apartment 1201, 1316 Carling Avenue, Ottawa, Ontario K1Z 7L1 (CA). BENKEL, Bernhard, F. [CA/CA]; 293 Summit Avenue, Ottawa, Ontario K1H 5Z7 (CA).			

(54) Title: TRANS-SOMATICS WITH GENE TRANSFER INTO MAMMARY EPITHELIAL CELLS



(57) Abstract

A method is described to transfer a gene encoding a valuable compound, such as a pharmaceutical, into the secretory cells of the mammary gland to produce a new compound into the milk or to alter the composition of the milk. In this method the packaging cell line producing the viral-derived particles is infused into the mammary gland. The packaging cells will attach and survive for a period of time within the mammary gland. While the cells are viable, they will supply a continuous source of viral-derived particles to trans-infect the maximum number of mammary epithelial cells. After a period of time in the mammary gland, both the particles and the packaging cells will be destroyed by natural mechanisms while the trans-infected mammary epithelial cells continue to express gene(s) encoding the valuable compound or gene(s) to alter the composition of the milk. One or more genes can be trans-infected including DNA sequences that contribute to the efficient production of an active compound or to its stability. The packaging cells and the viral-derived particles used in this method can be those which trans-infect dividing or non-dividing cells and can be used either singly or together. This method can be used alone or in combination with other novel methods designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells. Increasing the trans-infection of the mammary epithelial cells with the viral particles will result in a higher concentration of the valuable compound in the milk.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	R	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TRANS-SOMATICS WITH GENE TRANSFER INTO MAMMARY EPITHELIAL CELLS

5

FIELD OF INVENTION

The present invention relates to a method of producing value-added milk by the incorporation of specific DNA sequence(s) into the cells of the mammary gland. The term "value-added milk" is meant to mean milk containing a valuable compound, such as a pharmaceutical, as well as milk with a changed composition so that the market value of the milk is enhanced.

10

BACKGROUND OF THE INVENTION

This invention is based upon a technique to transfer a gene, and related non-translated control sequences, into the secretory cells of the mammary gland to produce new compounds in milk and/or to alter the milk composition.

15

An example of a compound produced into milk by this method would be a pharmaceutical which cannot be manufactured in a biologically active state. This invention provides an alternative method of producing such pharmaceuticals into milk using the synthetic capabilities of the mammary epithelial cell.

20

Mammals produce copious amounts of complex proteins into milk to provide nutrition for their young. To harness this capability, the DNA of, for example a valuable pharmaceutical, can be inserted into a mammary epithelial cell and this cell then will produce the active, pharmaceutical compound into the secreted milk. In a cow, the udder will act as a receptacle to hold the milk until it can be collected. The milk containing the added compound can be processed to extract and purify this pharmaceutical compound for subsequent sale, possibly to the medical and/or veterinary communities, or the milk could be consumed directly as a therapeutic

25

30

agent.

At present there are two basic techniques that can be used to produce value-added milk. The first is to create a transgenic animal by microinjection or transfection of foreign DNA into an ovum or a fertilized egg. Incorporation of DNA at this stage in development generally results in a **transgenic** animal which carries the inserted DNA in every cell.

There are positive and negative aspects of producing a transgenic animal which expresses foreign proteins in its milk. A positive point is that a single founder animal can create a population of transgenic animals by natural reproduction. However, progenies do not always produce the exogenous protein at the same level as the original animal. Negative aspects include the technically difficult procedures required to produce the animal and the long time between adding the foreign DNA and harvesting the exogenous protein. In addition, the presence of even very small amounts of an active pharmaceutical in every tissue may be detrimental to the health of the animal.

An alternative method is to produce value-added milk by adding the desired DNA only to the cells of the mammary gland of the animal. This results in a **trans-somatic** animal (or chimera) which contains the inserted DNA essentially in only one tissue, the mammary gland.

Trans-somatic animals have the advantage that they can be produced with less technical difficulty. They also can be produced quickly so that there is a period of only weeks to months between adding the foreign DNA and harvesting the exogenous protein. Moreover, since only one tissue contains the added DNA and produces the resulting compound, health risks to the trans-somatic animal are reduced. Although the DNA is not passed on to the progeny, this is compensated for by the ease and speed with which a trans-somatic animal can be produced.

A trans-somatic goat which expresses human growth hormone (hGH) into milk has been produced by Archer et al. (1994). In Archer the viral-derived particles were infused into the mammary gland for approximately every two days for two weeks. The levels of the compound, human growth hormone, which was used as an example, were very low and approached background levels after the first day. Also Gould et al. (United States Patent 5,215,904) described a method for increasing the rate of mitosis of mammary epithelial cells and then exposing these cells to viral particles for integration of the desired DNA into the epithelial cell.

To produce either a trans-somatic or a transgenic animal, exogenous DNA must pass through the exterior cell membrane. Eukaryotic cells have evolved a membrane which is impervious to most substances including heterologous DNA. Numerous techniques have been developed to bypass this barrier. These include:

- electroporation,
- carrier lipids (liposomes, negative, positive or neutral charged vesicles),
- mechanical wounding of cells including microinjection, liquid or air-jet pressure and scrape loading,
- use of particles composed partially or wholly of viral proteins.

Methods which have successfully produced trans-somatic animals include:

1) Arterial injection of DNA carried in liposomes (small lipid vesicles) was used to produce a trans-somatic mouse (Thierry et al. 1995). This technique can be adapted to deliver DNA to the mammary gland by injection into the major artery serving the mammary gland but circulation of the blood carrying the DNA can result in transfection of multiple tissues.

2) Direct injection of the DNA into tissues was used successfully to add foreign DNA to muscle and other tissues (Furth et al. 1992). This technique can be adapted to inject virus-like particles, carrying the foreign DNA, directly into the tissue of the udder.

3) Use of viral-derived particles carrying DNA coding for human growth

hormone (hGH) were infused through the teat canal, for example by Archer et al. (1994). This resulted in production of trans-somatic goats which expressed hGH into the milk.

5 Viruses reproduce within cells and therefore have evolved a technique to bypass the protective cell membrane to deliver the viral genome (DNA) into a host cell. To enter a cell, protein(s) of the outer viral shells first bind to receptors on the cell surface and then the virus is internalized.

10 The method used by Archer involves transfecting a cell line with DNA coding for various, but not all, proteins of a virus. This cell line, called a “**packaging cell line**”, will produce empty virus shells which can bind to receptors on the host cell membrane. When heterologous DNA, coding for a pharmaceutical or other milk modification, is transfected into the packaging cell line, this DNA will be packaged
15 into the viral-derived particle. When the viral-derived particle comes in contact with a milk-producing cell, the viral proteins of the shell ensure that the heterologous DNA is carried into the cell. Other viral proteins, associated with the particle, integrate the heterologous DNA into the genome of the host cell so that the protein encoded by the DNA can be expressed. In this method the viral-derived particles are used to
20 introduce the heterologous DNA into the mammary gland.

 The trans-somatic methods of the prior art offer advantages over the transgenic method; however the very low levels of foreign protein in the milk of the trans-somatic animal have limited the commercial success of these methods.

25

 Thus the present invention is directed to methods of improving the yield of the foreign protein in the milk of a trans-somatic animal.

SUMMARY OF THE INVENTION

30 The present invention relates to a method of producing valuable compounds into milk and/or changing the composition of milk so as to enhance its properties

and/or its marketability. More specifically the present invention relates to the addition of specific DNA sequences, including non-translated regulatory sequences, to the cells of the mammary gland and the subsequent expression of compound(s) encoded by that DNA into the milk. Other DNA sequences that enhance the efficiency of production of the compound, enhance the stability of the compound, or result in biological activity of the compound can also be added to the mammary epithelial cells either at the same time or at a different time.

The novel method of the present invention involves the use of viral-derived particles and packaging cells which produce these particles for infusion into the mammary gland through the teat canal. The packaging cells will attach and survive for a period of time within the mammary gland. While the cells are viable, they will supply a continuous source of viral-derived particles. These viral-derived particles trans-infect only dividing cells and are destroyed relatively quickly in the mammary gland. Thus a continuous supply of viral-derived particles from the packaging cells present in the mammary gland will ensure that viral-derived particles are present and can trans-infect the mammary epithelial cells whenever they divide.

The packaging cells and viral-derived particles can be from retroviruses and from non-retroviruses. Most retroviral-derived particles trans-infect only dividing cells. Non-retroviral particles such as those from adenovirus, Epstein-Barr virus, or other viruses trans-infect non-dividing cells. Thus a mixture of the two types of particles, and the associated packaging cells if needed, will ensure delivery of the packaged DNA to the maximum number of cells. Moreover, DNA can be packaged into viral-derived particles *in vitro* and these can be used for trans-infection as well.

This method can be used alone or in combination with other novel methods designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells. Increasing the trans-infection of the mammary epithelial cells with the viral particles will result in a higher concentration of the valuable compound in the milk along with possible other compounds produced from

the inserted DNA that will enhance the efficient production, stability or activity of the compound.

Thus according to the present invention there is provided a method of
5 producing a trans-somatic mammal, wherein said method provides the incorporation
of a DNA sequence into the secretory cells of the mammary gland to alter the
composition of the milk, comprising the steps of: providing a vector containing a
DNA sequence encoding a valuable compound; packaging said vector into a cell line;
preparing a solution comprising the packaged vector and cell line producing said
10 packaged vector; and delivering said solution into the mammary gland to allow the
incorporation of the DNA into the secretory cells of the mammary gland.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will become more apparent from the
15 following description in which reference is made to the appended drawings wherein:
FIGURE 1 shows the presence of amylase in an udder infused with Clone 10 (left
hind quarter) and Clone 12 (right hind quarter). The left front quarter was left
untouched as a negative control and the right front quarter was infused with DMEM
and Polybrene but no cells, to serve as a further negative control. Lanes 1, 2 & 3, early
20 premilk from 3 quarters of cow #99. Lane 1, control quarter (RF-); Lane 2, treated
quarter (RH+); Lane 3, treated quarter (LH+). Lanes 4, 5 & 6, late premilk from cow
#99. Lane 4, treated quarter (LH+); Lane 5, treated quarter (RH+); Lane 6, control
quarter (RH-). Lane 7, mixture of pig and chicken amylase standards; Lane 8, chicken
amylase standard.

25 **FIGURE 2** is a Western blot showing the presence of tPA in an udder infused with
Clone 1. Lane 1, premilk from treated quarter (LH+) of cow #56; Lane 2, premilk
from control quarter (LF-) of cow #56; Lane 3, premilk from treated quarter (RF+) of
cow #90.

30 DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention relates to a method to transfer a gene or genes, and

related non-translated control sequences into the secretory cells of a mammary gland to produce "value-added milk". The term "value-added milk" is meant to mean milk containing a valuable compound, such as a pharmaceutical, as well as milk with a changed composition so that the market value of the milk is enhanced.

5

Pharmaceuticals according to the present invention can include, but are not limited to: a tissue plasminogen activator, a blood clotting factor, an antibody, a protein to aid in weight reduction, a galactosyltransferase, a growth factor, an oncoprotein, a protease inhibitor, a hormone, a milk protein, a hormone receptor, a tumor suppressor protein, an aging inhibitor, or an erythropoietin.

10

According to the present invention there is provided a suitable DNA vector (plasmid) containing the desired DNA sequence encoding the heterologous protein (valuable compound) and associated regulatory sequences such as promoters, enhancers, introns, signal sequences, etc. Other sequences to produce compounds that increase efficient production, enhanced stability or are involved in biological activity of the compound can be included in the same or another DNA vector.

15

In one embodiment the vector is based on the pLXSN, pLNCX, or pLNSX plasmids provided under license from Fred Hutchinson Cancer Research Center.

20

According to the present invention the delivery of the DNA to the cells of the mammary gland is accomplished by the use of viral-derived particles and packaging cells, which produce these particles, for infusion into the mammary gland through the teat canal. This infusion is a standard veterinary practice and usually involves the use of a cannula for insertion into the teat canal, the cannula being attached to a syringe containing a solution of the packaging cells and viral-derived particles.

25

It has already been established that such particles derived from retrovirus trans-infect only dividing cells. Thus, the infusion of the particles and the packaging cells takes place when mammary cell division is naturally at a high level. In the

30

present invention heifers at 5 to 7 months pregnancy were used. It would also be possible to use non-pregnant mammals treated with hormones to induce mammary cell division and lactation prior to particle and cell infusion. However, this method would involve additional handling of the animal and thus is not preferred.

5

Other types of viral-derived particles and associated packaging cell lines, such as those based on adenovirus, Epstein-Barr virus, or other viruses can also be used. These non-retroviral derived particles can infect non-dividing cells. If used in combination with the retroviral derived particles described above, the maximum
10 number of cells will receive the desired DNA. In addition, particles to deliver DNA can be manufactured *in vitro* and use of these alone or in combination with the above described particles will enhance the number of mammary epithelial cells which incorporate the desired DNA. An example of particles which are constructed *in vitro* is described or referred to in Morsy and Caskey (1997).

15

The present invention is applicable to all mammals and is especially applicable to all non-human mammals. Goats, sheep and cows are preferred. Cows with their inherent large volume milk production are particularly preferred.

20

The packaging cells will attach and survive for a period of time within the mammary gland. The reason for the presence of the cells is to supply a continuous source of the viral-derived particles to trans-infect the maximum number of mammary epithelial cells. Both the packaging cells and the viral-derived particles are eventually destroyed in the mammary gland; however, considering the fragile nature of the
25 particles *in vitro*, they are likely destroyed within days. The cells, by contrast, may persist much longer. When cells were infused into the udder, and the udder subsequently flushed and assayed for the presence of cells (dead and alive), most of the cells could not be flushed out. Cells were seen in the wash for 3 days after infusion; of those cells that were flushed out, a large majority remain viable,
30 suggesting that most of the cells have become attached to the udder. In prior art methods (for example Archer et al. 1994), the particles are infused into the udder

approximately every two days for two weeks. In the present invention no subsequent infusions are necessary. Thus an advantage of the present invention over the prior art is a reduction in the handling of the animal.

5 In prior arts methods (for example, Archer et al. 1994), large scale tissue culture was required to supply sufficient numbers of particles for multiple infusions. An advantage of the present invention over the prior art is that preparation of a large number of particles is not required.

10 In prior arts methods (for example, Archer et al. 1994), the preparation of a stock solution of viral-particles required ultra-centrifugation and resuspension of the particles. A further advantage of the present invention is that no ultracentrifugation is involved. Centrifugation and other handling techniques can destroy the relatively
15 fragile particles. In the present invention, handling of the particles is minimal, increasing the probability that the particles present will remain intact and useful.

The above cited advantages are in addition to the improvement in yield of the compound in the milk, which has already been described above.

20 This method can be used alone or in combination with other methods of the present invention to increase the incorporation of DNA from the viral-derived particles. The additional methods of the present invention are all designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells.

25 In one embodiment, the teat canal and udder is first emptied by milking or under negative pressure. Then the udder is flushed with an osmotically-balanced solution which is infused into the teat canal and udder until the udder is full. This solution is removed by milking or under negative pressure and the desired suspension
30 is infused into the udder. In an alternative procedure, the teat canal is not emptied first but is directly filled with an osmotically-balanced solution which is then removed

by milking or under negative pressure.

Flushing of the udder serves two purposes; it removes the thick, secreted fluid that is normally present and it forces open the ductwork to allow better access of the packaging cells and viral-derived particles which will be inserted in the next step of the procedure. An example of a suitable osmotically-balanced solution includes saline solution, but can include any other buffered solutions, and also can include the packaging cell grown medium.

External massage applied several times a day to the mammary gland improves the circulation of the viral-derived particles and results in more secretory cells in the mammary gland being exposed to the viral-derived particles and thus more cells will incorporate the DNA carried in these particles.

In another embodiment, the packaging cells are grown on a commercially available matrix (designed to support growth and replication of tissue culture cells). This solid support matrix can include gelatin, glass, collagen or plastic beads. Cytodex beads or Cultisphere (purchased from Sigma) are two specific examples of useful support means. The beads, with cells adhering to them, are infused into the mammary gland through the teat canal along with a suspension of DNA-containing viral-derived particles. The beads remain in the mammary gland. External massage applied several times a day to the mammary gland recirculates the beads and helps to distribute the viral-derived particles that are produced by the packaging cells growing on the beads. The presence of the packaging cells on beads also ensures the continuous presence of many more DNA-containing viral-derived particles. Concomitantly more secretory cells in the mammary gland will incorporate the DNA carried within these viral particles and the production of the desired protein will increase accordingly. The beads and any cells remaining on them will eventually be removed when milking is begun.

30

In another embodiment, the infusion of cells (with or without growth on

beads) and viral-derived particles containing the desired DNA is followed by infusion of a substance which is more dense than the water-based suspension fluids, used for cell infusion, such as growth medium (Dulbecco's modified Eagle's medium [DMEM], phosphate buffered saline [PBS], etc.). This dense fluid, which in one
5 example is composed of silicone, displaces the aqueous solutions containing the packaging cells and the viral-derived particles upwards into the ductwork of the mammary gland. This prevents collection of the packaging cells in the cistern of the udder and positions the viral-derived cells and the viral-derived particles up into the ducts of the mammary gland. Thus, the viral-derived particles are positioned near the
10 dividing cells in the alveoli of the mammary gland and allow more of the DNA carried in the viral-derived particles to be incorporated. Any physiologically compatible inert fluid that has a density greater than that of the infusion solution can be used according to this embodiment of the present invention.

15 Thus, the present invention consists of the following procedure, which can be used alone or in combination with optional methods of the present invention, to deliver heterologous DNA to milk producing cells. In this procedure the following steps occur:

- 20 1) A vector containing the desired DNA sequence(s) is constructed and is transfected by standard means into a packaging cell line.
- 2) A solution containing the packaging cell line, producing viral-derived particles containing the desired DNA sequence(s), and viral-derived particles, is infused into the mammary gland through the teat canal. The packaging cells attach to the epithelial cells of the mammary gland, remain viable and produce viral-derived
25 particles.
- 3) The DNA becomes incorporated into the secretory cells of the mammary gland.
- 4) The milk containing the product induced by addition of the desired DNA is milked from the cistern. The product is purified from the milk or the milk,
30 containing the product, is consumed.

The basic technique can be modified by the addition of one or more of the following steps:

- 1) The udder is flushed with an osmotically-balanced solution.
- 2) The packaging cells are grown on a matrix designed to support proliferation of eukaryotic cells, such as Cytodex beads, and then infused through the teat canal. The cells will remain in the mammary gland and continue to produce viral-derived particles for a period of at least 3 days.
- 3) After infusion of the packaging cells (either as a suspension or grown on a matrix), a compound which is denser than aqueous solutions, such as silicone, is infused into the mammary gland to force the aqueous solutions carrying the packaging cells and viral-derived particles up and into the region of the mammary gland where the DNA can be incorporated into the milk producing cells. The dense compound, if it has been added, and any unattached cells as well as the matrix, if used, is removed from the mammary gland cistern by milking at an appropriate time after infusion. An appropriate time is defined as after the majority of packaging cells attach and after there is sufficient production of viral-derived particles. An example of an appropriate time would be at least 3 days, however shorter or longer periods may also be used. The packaging cells which are not removed at this time die and are removed by the recipient's natural mechanisms.
- 4) External massage applied several times a day to the mammary gland will recirculate the viral-derived particles and the packaging cells, provided either as a suspension or grown on a matrix. This helps to distribute the viral-particles and the cells and increases the incorporation of the DNA carried in these particles into the secretory cells.

While this invention is described in detail with particular reference to preferred embodiments thereof, said embodiments are offered to illustrate but do not limit the invention.

EXAMPLES

Example 1: Preparation of plasmids carrying the desired gene and various control sequences for use in retroviral particle delivery to bovine mammary epithelial cells

5 As a system to transfect the mammary epithelial cells with a desired gene, the PG13 packaging cell line was acquired under license from Fred Hutchinson Cancer Research Center. This system was used because it produces retroviral particles containing the gibbon ape leukemia virus envelope (Galv) which facilitates transfection of bovine cells. To package the desired gene "X" into retroviral particles,
10 the plasmids, pLXSN, pLNCX, pLNSX and pLN, also were acquired under license from Fred Hutchinson Cancer Research Center.

Modifications of plasmids:

15 In order to have an alternative method to select cell clones containing the desired gene, we replaced the *neomycin* (*neo*) gene with the *hygromycin* (*hyg*) gene in pLXSN, pLNSX and pLNCX. This was done by long-range PCR-amplification of the region around the *neo* gene then ligating the PCR product with the *hyg* gene which was amplified from the plasmid pREP4 (purchased from Invitrogen). The resulting plasmids were called pLXSH, pLHSX and pLHCX where "L" represents the Moloney
20 murine virus long terminal repeat (LTR) acting as a promoter, "S" is the SV40 promoter and "C" is the cytomegalovirus promoter region.

25 To put the desired gene, "X", under the control of a constitutive promoter, the cytomegalovirus promoter region in pLNCX and pLHCX was removed by restriction digestion and replaced with the beta actin promoter to make pLNAX and pLHAX. The beta actin promoter sequence was derived using PCR from the pJ6 Ω plasmid purchased from ATCC (catalog no. 37723).

30 In order to avoid transcription interference between the gene used for selection and the gene used to produce the desired protein, transcription from both genes was coupled by replacing the SV40 promoter from the plasmids pLXSN and pLXSH with

an internal ribosomal entry site (IRES). The resulting plasmids, pLAI_N and pLAI_H, express both the selection gene and the inserted gene under the same (LTR) promoter. The IRES in these plasmids provides the translation initiation site within the transcript, allowing the downstream gene product to be produced. The IRES used
5 here is identical to the IRES found in the plasmid pIRES1_{neo} purchased from Clontech. The sequences for pLAI_N and pLAI_H, where A in this case is chicken amylase but which can be any desired protein, are shown in SEQ ID No:1 and SEQ ID No: 2, respectively.

10 In order to increase retroviral titre or stability of the transcript, or to increase the expression level of the desired gene during lactation, or to allow translation of more than one protein from the same transcript, the basic plasmid, pLNCX, was modified. In one modification, the selection gene was removed to minimize the size of the resulting plasmid, pLX. In another modification, the CMV promoter was
15 replaced with the murine mammary tumour virus (M) LTR promoter to improve transcription of the resulting plasmid, pLNMX, during lactation. The sequence for pLNMX is shown in SEQ ID No: 3.

In another modification, a wild-type IRES was modified so that the ATG
20 codon at position 10 is destroyed and the sequence downstream of the ATG codon at position 11 codes for the desired gene, "X", in a plasmid such as pLNMi₂X. The sequence for this IRES modification (i₂) is included within the sequence for pLNMi₂X, shown in SEQ ID No: 4.

25 **Example 2: Preparation of cell clones producing viral-derived particles carrying the chicken amylase gene as a "marker" protein**

The two packaging cell lines used in this experiment were purchased from ATCC, PA317 (catalog no. CRL-9078) and PG13 (catalog no. CRL-10686). A description of both PA317 and PG13 and their use can be found in Miller et al. 1990.

30

To develop and optimize the transfection of mammary epithelial cells using

the retroviral particle delivery system, we used a stable and readily detectable marker protein, chicken amylase, in some experiments. Chicken amylase migrates at a unique position by native gel electrophoresis and can be differentiated from bovine or other amylases. To produce a PG13-derived cell line (a clone) producing retroviral particles which carried chicken amylase under the control of the beta actin promoter, the following procedure was done.

The pLH(A)amy plasmid with *hygromycin* (H) driven by the LTR promoter and with *amylase* (amy) driven by the beta actin promoter (A), was produced by standard recombinant techniques. pLH(A)amy was transiently transfected by the calcium phosphate technique into the PA317 packaging cell line. The transfected PA317 cells produce viral particles containing the amy RNA into the supernatant. The amphotropic viral envelope protein of these particles allows entry into cells of most species including the PG13 packaging cells in a process called trans-infection. Empirically it has been determined that trans-infection produces PG13 clones with a higher rate of particle production as compared to PG13 clones produced by other means of DNA insertion (particle bombardment, calcium phosphate or liposome transfection). Therefore, the viral-derived particles in the supernatant of the transfected PA317 cells were used to trans-infect the PG13 packaging cell line. The resulting clones were selected using 700 ug/ml hygromycin in DMEM with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin for 14 days. Clones were picked using cloning rings and grown as separate cell lines.

These PG13 amy clones were tested for amylase production by native gel electrophoresis of α -amylase. The α -amylase samples in loading buffer (0.1M tris-borate pH 8.5, 10% sucrose, 10mM magnesium chloride) were electrophoresed for 3-4 hours at 250 volts, with cooling, on a 5.5% acrylamide gel containing 0.1M tris-borate pH 8.5. The electrophoresis buffer was 0.1M tris-borate pH 8.5. The gel was then placed with gentle shaking for 1 h at room temperature in a solution of 2% soluble starch, 10mM calcium chloride, 50mM tris-HCl pH 7.5. The gel was briefly rinsed in water, then placed in a dilute solution of iodine (I_2 : KI : water is about 1 : 2 :

2000) until the amylase signal shows as a clear band on the gel.

5 All packaging cells produce filled retroviral particles which contain the desired gene and empty particles which do not carry the desired gene. To increase the number of filled retroviral particles, hygromycin-resistant PG13 amy clones producing high amounts of amylase were **supertransfected** with a second plasmid, pLN(A)amy, which also carried the amylase gene but which has *neomycin* as the clone selection agent. In this procedure, first pLN(A)amy was transfected into the PA317 cell line by the calcium phosphate procedure, and then the viral-derived particles in the supernatant of the transfected PA317 amy-containing cells were used to trans-infect a PG13/pLH(A)amy clone. The PG13/pLH(A) clone which was supertransfected was chosen on the basis of high amylase production. Superclones, containing both pLN(A)amy and pLH(A)amy sequences were obtained by selecting in the presence of 1000 ug/ml G418 and 700 ug/ml hygromycin as described above. The surviving clones were picked and grown up for further testing. Although a marker protein, amylase, was used in these experiments to optimize filling of particles, it is obvious that the same procedure can be done where another protein, such as a pharmaceutical protein, is used instead of the amylase.

20 The superclones producing the highest levels of amylase were analyzed for particle production by the following method. For each clone to be tested, the supernatant containing viral-derived particles was used to trans-infect HeLa 229 (human cervical carcinoma) (purchased from ATCC catalog no. CCL-2.1) and Et2 (bovine mammary) cells (provided by Dr. Boris Zavizion, University of Vermont, Burlington, Vt.). Depending on the resistance gene contained in the plasmid, the trans-infected cells were treated with either 700 ug/ml hygromycin or 1000 ug/ml neomycin, or both, and the resulting colonies were counted. Each colony is the result of one infective (filled) particle. The clone producing the highest number of colonies was selected to be grown for subsequent infusion into the heifer udder. In the specific example shown in Figure 1, clone 10 produced the highest number of viral-derived particles and was designated as PG13/LH/LN(A)amy.

Before a clone can be infused into the udder, it must be tested to determine that it does not produce replication-competent (called "helper") virus. Gene therapy is based on the assumption that the viral-derived particles can carry the desired DNA (i.e. cDNA for amylase or another protein) into the target cell but that once in the cell, the virus cannot reproduce itself. There are two methods to check if helper virus is being produced by the trans-infected packaging cell line. These are described in detail in Cepko, 1992. The first method is to analyze the supernatant of the HeLa and Et2 cells for horizontal spread of hygromycin and/or neomycin resistance. The second method is to look for the presence of reverse transcriptase above background levels in the supernatant of the trans-infected HeLa and Et2 cells. If trans-infection with the supernatant from HeLa and Et2 cells does not produce hygromycin and/or neomycin resistant colonies and if there is no reverse transcriptase above the level found in control cells, then it can be assumed that the particle producing clone, in this case PG13/LH/LN(A)amy, is not producing "helper" virus and therefore can be used for infusion into the udder. We followed the procedures detailed in the Cepko reference and found neither colony nor reverse transcriptase production.

Example 3: Infusion of clones producing retroviral-derived particles which carry a desired gene such as the amylase marker protein

In one example, the cell clone PG13/LH/LN(A)amy, which expresses chicken amylase as a marker protein, was infused into the udder of a 7 month pregnant heifer, #99. Before infusion with the cell clone, each quarter of the udder was flushed with 250ml of saline solution at 37° C using the catheter portion of an angiocath G-18 catheter attached to a 140 cc Monoject syringe with a Luer lock attachment (both purchased from CDMV, Saint-Hyacinthe, Quebec). The infusate was then milked out and measured to determine the volume of cell solution which could be administered to this particular quarter of this specific heifer.

Two superclones, designated as PG13/LH/LN(A)amy Clone 10 and PG13/LH/LN(A)amy Clone 12, were grown in standard tissue culture flasks until the total cell number (in an appropriate number of flasks) was $>2 \times 10^8$ cells/clone. The

cells were trypsinized, counted and resuspended at 1×10^8 cells in 250 ml DMEM without serum but containing 80 ug/ml of Polybrene to facilitate particle adsorption to the mammary epithelial cells.

5 The udder has four separate quarters. The left front quarter was left untouched as a negative control (LF-). The front right quarter was flushed with saline and infused with 250 ml DMEM plus 80 ug/ml Polybrene but with NO cells added and served as a negative control (RF-). The right hind quarter was infused with 1×10^8 Clone 12 cells in 250 ml DMEM plus Polybrene (RH+) and the left hind quarter was
10 infused 1×10^8 Clone 10 cells in 250 ml DMEM plus Polybrene (LH+). The infusate was not removed. The udder was massaged 3 times a day, morning, noon and night, to help to distribute the cells which tend to settle into the cistern of the udder. Three weeks post infusion, the udder was "stripped" (all secretions were milked by hand from each quarter) which removed about 7 to 10 ml per quarter of a viscous, serum-
15 like fluid. This was designated as "early premilk". Eight weeks post infusion the udder was stripped again, producing about 25 ml per quarter of a slightly cloudy, viscous fluid designated as "late premilk". The samples from the right front control quarter RF(-) and the two infused quarters, the right hind, RH(+) and the left hind, LH(+) were analyzed for the presence of active amylase as previously described (see
20 Figure 1).

Figure 1 shows that in the early premilk sample, amylase is present in both infused quarters (RH) and (LH) while the control quarter (RF) contains no amylase. In the late premilk, the negative control quarter (RF) continues to show no amylase
25 activity. Clone 10, left hind quarter, shows the highest amylase activity. Clone 12, right hind quarter, has decreased activity compared to the early premilk sample, but a small amount of amylase activity was detected. The samples loaded represent equal volumes (100 ul/lane) of the premilk samples. No attempt was made to load equal amounts of protein. The apparent reduction in the amount of amylase present between
30 early and late premilk samples is caused by increased volume of the late premilk samples relative to the volume of the early premilk samples.

Example 4: Preparation of a clone producing viral-derived particles that carry the tPA gene and infusion of this clone into the udder of a pregnant heifer

Tissue plasminogen activator (tPA) is used to treat heart attack and stroke by dissolving blood clots. We selected human tPA to be the first pharmaceutical product to be produced by our method in bovine milk. The ptPA-K plasmid, containing the mutated cDNA sequence for human tPA (where the amino acids KHRH 296-299 was mutated to AAAA, i.e. the "K" mutation), was purchased from ATCC (American Type Culture Collection, catalog no. 68059). Two additional mutations were incorporated into ptPA-K to form ptPA-TNK: the amino acid threonine at position 103 was mutated to asparagine (the "T" mutation), and the amino acid asparagine at position 117 was mutated to glutamine (the "N" mutation). The tPA amino acid sequence and a description of the above modifications can be found in Pennica et al. 1983. Both mutations were produced by using mismatched oligonucleotides containing the altered nucleotide sequence as primers for PCR amplification. The tPA-TNK gene was subsequently excised by restriction digestion and ligated into the pLXSH plasmid to make pL(tPA)SH.

The resulting PG13(tPA) clones were analyzed for tPA production by colorimetric determination using Spectrozyme (# 444 purchased from American Diagnostica Inc.). Clones which showed high levels of tPA were then checked for production of filled particles by colony counts (as described previously) and were safety checked to insure that no replication competent virus was being produced and that there was no reverse transcriptase production above that found as background in HeLa or ET2 cells. None of the clones tested produced replication competent virus by either of these tests. The clones with the highest particle production and highest level of tPA production were selected to be grown for infusion into the udder. In the following example, clone PG13/L(tPA)SH-1, was chosen for infusion into the udder.

In one example, Clone 1 (PG13/L(tPA)SH-1), which produces tPA, was infused into the udder of a seven and a half month pregnant heifer, #90 and into the

udder of a six and a half month pregnant heifer, #56. Before infusion of the clone and particles produced by it, each quarter of the udder in both heifers was flushed with 250ml of saline as described in Example 3. After milking out the saline, the right rear (RR) quarter of heifer #90 received 2.5×10^7 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum while the right front (RF) quarter received 1×10^8 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum. The left front (LF) quarter received 250 ml of DMEM as a control while the left rear (LR) quarter was the untreated control. Heifer # 56 received 2.5×10^7 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum in the left front quarter (LF+) and 1×10^8 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum in the right rear quarter (RR+). The right front quarter received 250 ml of DMEM as a control (RF-) while the left front (LF-) quarter was the untreated control. In both heifers, the infusate was not removed and the udder was massaged three times daily to help distribute the cells and particles up into the ductwork.

15

Four weeks post-infusion, the four quarters of both heifers were stripped to remove 5 to 9ml of the viscous, serum-like premilk fluid. The premilk samples from treated and control quarters of both heifers were analyzed for the presence of tPA by Western blotting. A Western blot showing the tPA results obtained from the best quarter of each heifer is shown in Figure 2.

20

For Western blotting, the premilk samples were adjusted to pH 4.5 with acetic acid and centrifuged at $13,000 \times g$ to pellet the "curd" fraction. The "whey" fraction contained in the supernatant was collected and diluted 1:5 with sample buffer. Samples of 20 ul were loaded onto a 7.5% SDS PAGE gel. To detect tPA, the gel was transferred to nitrocellulose and then blocked overnight in 5% bovine serum albumin (BSA). The blot was incubated for 2 hours with a polyclonal antibody to tPA, #385R, purchased from American Diagnostica, diluted 1:500 with PBS followed by extensive washing in PBS. The secondary antibody, horseradish peroxidase goat-anti-rabbit, diluted 1:5000 in PBS, was incubated with the blot for one hour then extensively washed. Detection of antibody staining of tPA was by enhanced chemi-

25

30

luminescence (ECL) Amersham Detect Kit. Specificity of the primary antibody was previously determined by Western blotting a control sample of commercial tPA purchased from American Diagnostica.

5 Results of Western blotting samples obtained from the untreated control quarter (LF-) and from one treated quarters of each heifer are shown in Figure 2. Lane 1 shows a strong tPA band in the premilk from the treated (LH+) quarter of heifer #56. The middle lane, lane 2, contains premilk from the (LF-) control quarter of cow #56. Lane 3 shows a tPA band in the premilk from the treated (RF+) quarter
10 of heifer #90. A faint smear in all 3 sample lanes is the result of non-specific binding of the antibody to an unidentified protein and should be disregarded.

**Example 5: Determination of viability and attachment of 3T3 cells to the surface
15 of the bovine udder.**

The cells used in this experiment were 3T3 cells (purchased from ATCC, catalog no. CCL-92) which had been transfected with luciferase as a marker protein. These 3T3 cells are essentially identical to the PG13 packaging cells except that the 3T3 cells have not been transfected with the retroviral genes that are found in the
20 packaging line.

Three quarters of the udder of a 5 month pregnant heifer and three quarters of the udder of a 7 month pregnant heifer were flushed with saline solution at 37° C using a standard veterinary infusion apparatus. The saline was then milked out and
25 measured to determine what quantity of medium with or without cells could be infused into that particular quarter. In both heifers, one udder quarter was left untreated as a negative control; a second quarter received only DMEM, the third quarter received 1×10^6 cells suspended in an appropriate amount of DMEM, and the fourth quarter received 1×10^7 cells also suspended in an appropriate amount of
30 DMEM. The quarters were then milked to produce about 10 ml of fluid at 3 hours, 24 hours, and 72 hours post-infusion.

The fluid obtained by milking was divided in half. One portion was cultured under standard conditions for 3T3 cells to determine if the cells were viable. The second portion was used in a luciferase assay to count the approximate number of 3T3-luciferase cells per ml in the fluid. A control was run simultaneously using known numbers of 3T3-luciferase cells and a curve drawn to determine the correlation of luciferase intensity with cell number.

The results of two experiments indicated that the highest number of cells were found 3 hours post infusion and progressively fewer cells were found in the fluid milked from the udder at 24 and 72 hours. However the cells which were milked out at 72 hours were viable. This is evidence that the cells are attaching to the udder surface and that those cells which were unattached (and therefore could be milked out of the udder) remained viable for the period of the experiment. This suggests that the 3T3 cells are not quickly destroyed by the factors in the environment of the udder. Thus PG13(tPA) cells can be expected to remain viable for at least a period of 3 days during which time they will continue to produce viral-derived particles and can therefore trans-infect a substantial number of mammary epithelial cells.

Table 1: Attachment of 3T3 cells to udder walls

Udder Quarter	Treatment	Attachment of 3T3 cells to udder interior at:		
		3 hours post-infusion	24 hours post-infusion	72 hours post-infusion
left hind	no treatment	-	-	-
left front	medium only	-	-	-
right hind	1 X 10 ⁶ cells	-	+/-	+
right front	1 x 10 ⁷ cells	+/-	++	++

Example 6: Infusion of 3T3 cells grown on a solid support means

The cells used in this experiment were 3T3 cells, as described in Example 2.

In this example however the cells were grown on Cytodex beads.

The cells growing on beads were infused into the udder of a 7 month pregnant heifer and subsequently removed 1, 2 and 3 days later as described in Example 2. Cells
5 were removed from beads and viability was determined by Trypan blue exclusion. The cells remained viable for the entire period.

Example 7: Use of Silicone to displace the cells and viral-derived particles

The cells used in this experiment were 3T3 cells, as described in Example 3.
10 The volume of the solution containing the cells and viral-derived particles was reduced by 50 ml, 25 ml, or 10 ml but the overall number of the cells remained constant.

After the solution was infused into the udder, as described in the preceding
15 examples, approximately 50 ml, 25 ml or 10 ml of silicone was infused into the mammary gland, using the methods previously described.

After three days the silicone was removed from the cistern by milking. No
reaction to the silicone was noted.

20

All scientific publications and patent documents are incorporated herein by reference.

References:

25

Archer, J.S., W.S. Kennan, M.N. Gould, R.D. Bremel. 1994. Human growth hormone (hGH) secretion in milk of goats after direct transfer of the hGH gene into the mammary gland by using replication-defective retrovirus vectors. Proc. Natl. Acad. Sci. USA, 91:6840-6844.

30

Cepko, C. 1992. Transduction of genes using retrovirus vectors. *In*: Short Protocols

in Molecular Biology, 2nd edition. Ed. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Struhl. Pub. by John Wiley & Sons. New York, N.Y. pp 9-30 to 9-45.

- 5 Furth, P.A., A. Shamay, R.J. Wall, L. Henninghausen. 1992. Gene transfer into somatic tissues by jet injection. *Analyt. Biochem.* 205:365-368.

Miller, A.D., D.G. Miller, J. V. Garcia, C.M. Lynch. 1990. Use of retroviral vectors for gene transfer and expression. *Meth. Enzymol.* 217: 581-599.

10

Morsy, M.A. and C.T. Caskey. 1997. Safe gene vectors made simpler. *Nature Biotech.* 15:17.

- 15 Pennica, D, W.E. Holmes, W.J. Kohr, R.N. Harkins, G.A. Vehaar, C.A. Ward, W.F. Bennett, E. Yelverton, P.H. Seeburg, H.L. Heyneker, D.V. Goeddel. 1983. Cloning and expression of human tissue-type plasminogen activator cDNA in *E. coli*. *Nature* 301: 214-221.

- 20 Thierry, A.R., Y. Lunardi-Iskandar, J.L. Bryant, P. Rabinovich, R.C. Gallo, L.C. Mahan. 1995. Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. *Proc. Natl. Acad. Sci. USA.* 92:9742-9746.

25 The present invention has been described with regard to preferred embodiments. However, it will be obvious to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as described in the following claims.

30

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Her Majesty in Right of Canada as Rep. by
Agriculture and Agri-Food Canada
- (B) STREET: Experimental Farm
- (C) CITY: Ottawa
- (D) STATE: Ontario
- (E) COUNTRY: Canada
- (F) POSTAL CODE (ZIP): K1A 0C6

- (ii) TITLE OF INVENTION: Production of Value-added Milk by
Incorporation of Specific DNA Sequences into Mammary
Epithelial Cells

- (iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: CA 0,000,000

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: CA 2,199,212
- (B) FILING DATE: 05-MAR-1997

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7699 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTGCTAG CAATTGCTAG CAATTGCTAG CAATTCATAC CAGATCACCG AAAACTGTCC 60
TCCAAATGTG TCCCCCTCAC ACTCCCAAAT TCGCGGGCTT CTGCCTCTTA GACCACTCTA 120

CCCTATTCCC CACACTCACC GGAGCCAAAG CCGCGGCCCT TCCGTTTCTT TGCTTTTGAA	180
AGACCCACC CGTAGGTGGC AAGCTAGCTT AAGTAACGCC ACTTTGCAAG GCATGGAAAA	240
ATACATAACT GAGAATAGAA AAGTTCAGAT CAAGGTCAGG AACAAAGAAA CAGCTGAATA	300
CCAAACAGGA TATCTGTGGT AAGCGGTTCC TGCCCCGGCT CAGGGCCAAG AACAGATGAG	360
ACAGCTGAGT GATGGGCCAA ACAGGATATC TGTGTAAGC AGTTCCTGCC CCGGCTCGGG	420
GCCAAGAACA GATGGTCCCC AGATGCGGTC CAGCCCTCAG CAGTTTCTAG TGAATCATCA	480
GATGTTTCCA GGGTGCCCCA AGGACCTGAA AATGACCCTG TACCTTATTT GAACTAACCA	540
ATCAGTTTCG TTCTCGCTTC TGTTGCGCGC CTTCCGCTCT CCGAGCTCAA TAAAAGAGCC	600
CACAACCCCT CACTCGGCGC GCCAGTCTTC CGATAGACTG CGTCGCCCGG GTACCCGTAT	660
TCCCAATAAA GCCTCTTGCT GTTTGCATCC GAATCGTGGT CTCGCTGTTC CTTGGGAGGG	720
TCTCCTCTGA GTGATTGACT ACCCACGACG GGGGTCTTTC ATTTGGGGGC TCGTCCGGGA	780
TTTGAGAGCC CCTGCCCAGG GACCACCGAC CCACCACCGG GAGGTAAGCT GGCCAGCAAC	840
TTATCTGTGT CTGTCCGATT GTCTAGTGTC TATGTTTGAT GTTATGCGCC TCGCTCTGTA	900
CTAGTTAGCT AACTAGCTCT GTATCTGGCG GACCCGTGGT GGAAGTGACG AGTTCTGAAC	960
ACCCGGCCGC AACCTGGGA GACGTCCCAG GGACTTTGGG GGCCGTTTTT GTGGCCCGAC	1020
CTGAGGAAGG GAGTCGATGT GGAATCCGAC CCCGTCAGGA TATGTGGTTC TGGTAGGAGA	1080
CGAGAACCTA AAACAGTTCC CGCCTCCGTC TGAATTTTGG CTTTCGGTTT GGAACCGAAG	1140
CCGCGCGTCT TGTCTGCTGC AGCGCTGCAG CATCGTTCTG TGTGTCTCT GTCTGACTGT	1200
GTTTCTGTAT TTGTCTGAAA ATTAGGGCCA GACTGTTACC ACTCCCTTAA GTTTGACCTT	1260
AGGTCACTGG AAAGATGTCG AGCGGATCGC TCACAACCAG TCGGTAGATG TCAAGAAGAG	1320
ACGTTGGGTT ACCTTCTGCT CTGCAGAATG GCCAACCTTT AACGTCGGAT GGCCGCGAGA	1380
CGGCACCTTT AACCGAGACC TCATCACCCA GGTTAAGATC AAGGTCTTTT CACCTGGCCC	1440
GCATGGACAC CCAGACCAGG TCCCCTACAT CGTGACCTGG GAAGCCTTGG CTTTTGACCC	1500
CCCTCCCTGG GTCAAGCCCT TTGTACACCC TAAGCCTCCG CCTCCTCTTC CTCCATCCGC	1560
CCCGTCTCTC CCCCTTGAAC CTCCTCGTTC GACCCCGCCT CGATCCTCCC TTTATCCAGC	1620
CCTCACTCCT TCTCTAGGCG CCGGAATTCG TTAAGTCGAC ATGGAAGTCC TTCTCCTCCT	1680
CGCAGCTGTC GGGCTTTGCT GGGCACAGTA CAATCCCAAC ACTCAGGCTG GGAGGACATC	1740
TATCGTGCAT CTCTTTGAAT GGCGCTGGGC CGACATTGCA CTGGAGTGCG AACACTATTT	1800

AGCTCCTAAT GGGTTTGGAG GAGTTCAGGT TTCTCCTCCA AATGAAAACA TTGTCATTAC	1860
TAATCCGAAC AGGCCCTGGT GGGAAAGATA CCAGCCCATC AGCTACAAGA TCTGCAGTCG	1920
ATCGGGCAAT GAAAATGAAT TCAGAGACAT GGTGACCAGA TGCAACAATG TTGGAGTTCCG	1980
TATTTATGTG GATGCTGTTG TCAATCACAT GTGTGGATCT ATGGGTGGCA CGGGCACCCA	2040
CTCAACATGT GGGAGCTATT TCAACACCGG GACTAGAGAT TTTCCCGCTG TGCCGTACTC	2100
TGCCTGGGAT TTCAATGACG GCAAATGTCA CACTGCAAGT GGAGACATCG AAAATTATGG	2160
GGACATGTAT CAGGTCCGGG ATTGCAAGTT GTCCAGCCTT CTTGATCTGG CTCTGGAGAA	2220
GGACTATGTA CGCTCAACAA TTGCAGCGTA CATGAATCAC CTCATTGATA TGGGTGTAGC	2280
AGGGTTCCGG ATCGATGCTG CCAAGCATAT GTGGCCAGGG GACATAAGAG CGTTTCTGGA	2340
CAAACTGCAC GATCTAAATA CTCAGTGGTT TTCAGCAGGA ACGAAACCCT TTATTTACCA	2400
AGAGGTAATT GACTTGGGAG GAGAGCCAAT CACAGGCAGT CAGTACTTTG GGAATGGCCG	2460
CGTGACAGAA TTCAAGTATG GTGCCAACT GGGGACGGTG ATCCGGAAGT GGAATGGAGA	2520
GAAGATGGCC TACTTAAAGA ACTGGGGAGA AGGCTGGGGC TTTGTGCCTT CTGACAGAGC	2580
CCTGGTGTTC GTGGATAACC ACGACAACCA GCGGGGGCAC GGGGCAGGCG GAGCTTCCAT	2640
TCTTACTTTC TGGGATGCCA GGCTTTATAA AATGGCGGTT GGTTCATGC TCGCTCATCC	2700
GTACGGGTTC ACACGGGTGA TGTCAAGTTA TCGTTGGCCA AGATATTTTCG AAAACGGAGT	2760
GGATGTTAAC GACTGGGTGG GACCACCAAG TAACTCGGAC GGATCGACGA AGTCCGTTAC	2820
AATCAACGCA GACACTACCT GTGGCAATGA CTGGGTCTGC GAACATCGCT GGCGACAAAT	2880
AAGGAACATG GTTATCTTCC GTAATGTGGT AGACGGTCAG CCTTCTCAA ACTGGTGGGA	2940
CAACGGGAGC AATCAAGTAG CTTTCGGTCG CGGCGACAGA GGCTTCATTG TCTTTAATAA	3000
TGATGACTGG TATATGAATG TCGATTGCA AACTGGTCTG CCTGCTGGAA CCTACTGCGA	3060
TGTTATTTCT GGACAAAAGG AAGGCAGTGC GTGTACTGGA AAGCAGGTGT ACGTTTCCTC	3120
GGATGGAAAG GCCAATTTCC AGATTAGTAA CAGCGATGAA GATCCATTG TTGCAATTCA	3180
CGTTGATGCC AAGTTATAAG CTTGAGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA	3240
TTCGGCTTGT CGACATCTAG GCGGCCAAT TCCGCCCCTC TCCCCCCCCC CCCTAACGTT	3300
ACTGGCCGAA GCCGCTTGGA ATAAGGCCGG TGTGTGTTG TCTATATGTG ATTTTCCACC	3360
ATATTGCCGT CTTTGGCAA TGTGAGGGCC CGGAAACCTG GCCCTGTCTT CTTGACGAGC	3420
ATTCCTAGGG GTCTTTCCCC TCTCGCCAAA GGAATGCAAG GTCTGTTGAA TGTCGTGAAG	3480

GAAGCAGTTC CTCTGGAAGC TTCTTGAAGA CAAACAACGT CTGTAGCGAC CCTTTGCAGG	3540
CAGCGGAACC CCCACCTGG CGACAGGTGC CTCTGCGGCC AAAAGCCACG TGTATAAGAT	3600
ACACCTGCAA AGGCGGCACA ACCCCAGTGC CACGTTGTGA GTTGATAGT TGTGGAAAGA	3660
GTCAAATGGC TCTCCTCAAG CGTAGTCAAC AAGGGGCTGA AGGATGCCCA GAAGGTACCC	3720
CATTGTATGG GAATCTGATC TGGGGCCTCG GTGCACATGC TTTACATGTG TTTAGTCGAG	3780
GTTAAAAAAG CTCTAGGCCC CCCGAACCAC GGGGACGTGG TTTTCCTTTG AAAAACACGA	3840
TGATAAGCTT GCCACAACCC GGGATAATTC CTGCAGCCAA TATGGGATCG GCCATTGAAC	3900
AAGATGGATT GCACGCAGGT TCTCCGGCCG CTTGGGTGGA GAGGCTATTG GGCTATGACT	3960
GGGCACAACA GACAATCGGC TGCTCTGATG CCGCCGTGTT CCGGCTGTCA GCGCAGGGGC	4020
GCCCCGTTCT TTTGTCAAG ACCGACCTGT CCGGTGCCCT GAATGAACTG CAGGACGAGG	4080
CAGCGCGGCT ATCGTGGCTG GCCACGACGG GCGTTCCTTG CGCAGCTGTG CTCGACGTTG	4140
TCACTGAAGC GGAAGGGAC TGGCTGCTAT TGGGCGAAGT GCCGGGGCAG GATCTCCTGT	4200
CATCTCACCT TGCTCCTGCC GAGAAAGTAT CCATCATGGC TGATGCAATG CGGCGGCTGC	4260
ATACGCTTGA TCCGGCTACC TGCCCATTCG ACCACCAAGC GAAACATCGC ATCGAGCGAG	4320
CACGTACTCG GATGGAAGCC GGTCTTGTCG ATCAGGATGA TCTGGACGAA GAGCATCAGG	4380
GGCTCGCGCC AGCCGAACTG TTCGCCAGGC TCAAGGCGCG CATGCCCGAC GGCGATGATC	4440
TCGTCGTGAC CCATGGCGAT GCCTGCTTGC CGAATATCAT GGTGGAAAAT GGCCGCTTTT	4500
CTGGATTTCAT CGACTGTGGC CGGCTGGGTG TGGCGGACCG CTATCAGGAC ATAGCGTTGG	4560
CTACCCGTGA TATTGCTGAA GAGCTTGGCG GCGAATGGGC TGACCGCTTC CTCGTGCTTT	4620
ACGGTATCGC CGCTCCCGAT TCGCAGCGCA TCGCCTTCTA TCGCCTTCTT GACGAGTTCT	4680
TCTGAGCGGG ACTCTGGGGT TCGATAAAAT AAAAGATTTT ATTTAGTCTC CAGAAAAAGG	4740
GGGGAATGAA AGACCCACCC TGTAGGTTTG GCAAGCTAGC TTAAGTAACG CCATTTTGCA	4800
AGGCATGGAA AAATACATAA CTGAGAATAG AGAAGTTCAG ATCAAGGTCA GGAACAGATG	4860
GAACAGCTGA ATATGGGCCA AACAGGATAT CTGTGGTAAG CAGTTCCTGC CCCGGCTCAG	4920
GGCCAAGAAC AGATGGAACA GCTGAATATG GGCCAAACAG GATATCTGTG GTAAGCAGTT	4980
CCTGCCCCGG CTCAGGGCCA AGAACAGATG GTCCCCAGAT GCGGTCCAGC CCTCAGCAGT	5040
TTCTAGAGAA CCATCAGATG TTTCCAGGGT GCCCAAGGA CCTGAAATGA CCCTGTGCCT	5100
TATTTGAACT AACCAATCAG TTCGCTTCTC GCTTCTGTTC GCGCGCTTCT GCTCCCCGAG	5160

CTCAATAAAA GAGCCCACAA CCCCTCACTC GGGGCGCCAG TCCTCCGATT GACTGAGTCG	5220
CCCCGGTACC CGTGTATCCA ATAAACCCTC TTGCAGTTGC ATCCGACTTG TGGTCTCGCT	5280
GTTCCTTGGG AGGGTCTCCT CTGAGTGATT GACTACCCGT CAGCGGGGGT CTTTCATTTG	5340
GGGGCTCGTC CGGGATCGGG AGACCCCTGC CCAGGGACCA CCGACCCACC ACCGGGAGGT	5400
AAGCTGGCTG CCTCGCGCGT TTCGGTGATG ACGGTGAAAA CCTCTGACAC ATGCAGCTCC	5460
CGGAGACGGT CACAGCTTGT CTGTAAGCGG ATGCCGGGAG CAGACAAGCC CGTCAGGGCG	5520
CGTCAGCGGG TGTGGCGGG TGTCGGGGCG CAGCCATGAC CCAGTCACGT AGCGATAGCG	5580
GAGTGATATAC TGGCTTAACT ATGCGGCATC AGAGCAGATT GTACTGAGAG TGCACCATAT	5640
GCGGTGTGAA ATACCGCACA GATGCGTAAG GAGAAAATAC CGCATCAGGC GCTCTTCCGC	5700
TTCTCGCTC ACTGACTCGC TGCCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA	5760
CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG	5820
AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA	5880
TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA	5940
CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCCTCTCC	6000
TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC	6060
GCTTTCTCAT AGCTCAGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTT GCTCCAAGCT	6120
GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACATCG	6180
TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG	6240
GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA	6300
CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG	6360
AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT	6420
TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT	6480
TTCTACGGGG TCTGACGCTC AGTGGAACGA AACTCACGT TAAGGGATTT TGGTCATGAG	6540
ATTATCAAAA AGGATCTTCA CCTAGATCCT TTAAATTAA AAATGAAGTT TTAAATCAAT	6600
CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC	6660
TATCTCAGCG ATCTGTCTAT TTCGTTATC CATAGTTGCC TGAATCCCCG TCGTGTAGAT	6720
AACTACGATA CGGGAGGGCT TACCATCTGG CCCAGTGCT GCAATGATAC CGCGAGACCC	6780
ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGAAGGG CCGAGCGCAG	6840

AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAAGCTAG	6900
AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTG CAGGCATCGT	6960
GGTGTACGCG TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCTAAC GATCAAGGCG	7020
AGTTACATGA TCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT	7080
TGTCAGAAGT AAGTTGGCCG CAGTGTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC	7140
TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC	7200
ATTCTGAGAA TAGTGTATGC GCGGACCGAG TTGCTCTTGC CCGGCGTCAA CACGGGATAA	7260
TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAACGTT CTTCGGGGCG	7320
AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC	7380
CAACTGATCT TCAGCATCTT TTAATTTTAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG	7440
GCAAAATGCC GCAAAAAAGG GAATAAGGCG GACACGGAAA TGTGAATAC TCATACTCTT	7500
CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT	7560
TGAATGTATT TAGAAAAATA AACAAATAGG GGTCCGCGC ACATTTCCCC GAAAAGTGCC	7620
ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GCGGTATCAC	7680
GAGGCCCTTT CGTCTTCAA	7699

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7980 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GAATTGCTAG CAATTGCTAG CAATTGCTAG CAATTCATAC CAGATCACCG AAAACTGTCC	60
TCCAAATGTG TCCCCCTCAC ACTCCCAAAT TCGCGGGCTT CTGCCTCTTA GACCACTCTA	120
CCCTATTCCC CACACTCACC GGAGCCAAAG CCGCGGCCCT TCGTTTCTT TGCTTTTGAA	180
AGACCCACCC CGTAGGTGGC AAGCTAGCTT AAGTAACGCC ACTTTGCAAG GCATGGAAAA	240
ATACATAACT GAGAATAGAA AAGTTCAGAT CAAGGTCAGG AACAAAGAAA CAGCTGAATA	300
CCAAACAGGA TATCTGTGGT AAGCGGTTCC TGCCCCGGCT CAGGGCCAAG AACAGATGAG	360

ACAGCTGAGT GATGGGCCAA ACAGGATATC TGTGGTAAGC AGTTCCTGCC CCGGCTCGGG	420
GCCAAGAACA GATGGTCCCC AGATGCGGTC CAGCCCTCAG CAGTTTCTAG TGAATCATCA	480
GATGTTTCCA GGGTGCCCCA AGGACCTGAA AATGACCCTG TACCTTATTT GAACTAACCA	540
ATCAGTTCGC TTCTCGCTTC TGTTGCGCGC CTTCCGCTCT CCGAGCTCAA TAAAAGAGCC	600
CACAACCCCT CACTCGGCGC GCCAGTCTTC CGATAGACTG CGTCGCCCCG GTACCCGTAT	660
TCCCAATAAA GCCTCTTGCT GTTTGCATCC GAATCGTGGT CTCGCTGTTT CTTGGGAGGG	720
TCTCCTCTGA GTGATTGACT ACCCAGCAGC GGGGTCTTTC ATTTGGGGGC TCGTCCGGGA	780
TTTGAGAGACC CCTGCCCAGG GACCACCGAC CCACCACCGG GAGGTAAGCT GGCCAGCAAC	840
TTATCTGTGT CTGTCCGATT GTCTAGTGTC TATGTTTGAT GTTATGCGCC TCGCTCTGTA	900
CTAGTTAGCT AACTAGCTCT GTATCTGGCG GACCCGTGGT GGAAGTGACG AGTTCTGAAC	960
ACCCGCGCGC AACCCTGGGA GACGTCCAG GGACTTTGGG GGCCGTTTTT GTGGCCCGAC	1020
CTGAGGAAGG GAGTCGATGT GGAATCCGAC CCCGTCAGGA TATGTGGTTC TGGTAGGAGA	1080
CGAGAACCTA AAACAGTTCC CGCCTCCGTC TGAATTTTTG CTTTCGGTTT GGAACCGAAG	1140
CCGCGCGTCT TGTCTGCTGC AGCGCTGCAG CATCGTTCTG TGTTGTCTCT GTCTGACTGT	1200
GTTTCTGTAT TTGTCTGAAA ATTAGGGCCA GACTGTTACC ACTCCCTTAA GTTTGACCTT	1260
AGGTCACTGG AAAGATGTCG AGCGGATCGC TCACAACCAG TCGGTAGATG TCAAGAAGAG	1320
ACGTTGGGTT ACCTTCTGCT CTGCAGAATG GCCAACCTTT AACGTCGGAT GGCCGCGAGA	1380
CGGCACCTTT AACCGAGACC TCATCACCCA GGTAAAGATC AAGGTCTTTT CACCTGGCCC	1440
GCATGGACAC CCAGACCAGG TCCCCTACAT CGTGACCTGG GAAGCCTTGG CTTTTGACCC	1500
CCCTCCCTGG GTCAAGCCCT TTGTACACCC TAAGCCTCCG CCTCCTCTTC CTCCATCCGC	1560
CCCGTCTCTC CCCCTTGAAC CTCCTCGTTC GACCCCGCCT CGATCCTCCC TTTATCCAGC	1620
CCTCACTCCT TCTCTAGGCG CCGGAATTCG TTAAGTCGAC ATGGAAGTCC TTCTCCTCCT	1680
CTCAGCTGTC GGGCTTTGCT GGGCACAGTA CAATCCCAAC ACTCAGGCTG GGAGGACATC	1740
TATCGTG CAT CTCTTTGAAT GGCGCTGGGC CGACATTGCA CTGGAGTGCG AACACTATTT	1800
AGCTCCTAAT GGGTTTGGAG GAGTTCAGGT TTCTCCTCCA AATGAAAACA TTGTCATTAC	1860
TAATCCGAAC AGGCCCTGGT GGGAAAGATA CCAGCCCATC AGCTACAAGA TCTGCAGTCG	1920
ATCGGGCAAT GAAAATGAAT TCAGAGACAT GGTGACCAGA TGCAACAATG TTGGAGTTCG	1980
TATTTATGTG GATGCTGTTG TCAATCACAT GTGTGGATCT ATGGGTGGCA CGGGCACCCA	2040

CTCAACATGT GGGAGCTATT TCAACACCGG GACTAGAGAT TTTCCCGCTG TGCCGTACTC	2100
TGCCTGGGAT TTCAATGACG GCAAATGTCA CACTGCAAGT GGAGACATCG AAAATTATGG	2160
GGACATGTAT CAGGTCCGGG ATTGCAAGTT GTCCAGCCTT CTTGATCTGG CTCTGGAGAA	2220
GGACTATGTA CGCTCAACAA TTGCAGCGTA CATGAATCAC CTCATTGATA TGGGTGTAGC	2280
AGGGTTCCGG ATCGATGCTG CCAAGCATAT GTGGCCAGGG GACATAAGAG CGTTTCTGGA	2340
CAAACTGCAC GATCTAAATA CTCAGTGGTT TTCAGCAGGA ACGAAACCCCT TTATTTACCA	2400
AGAGGTAATT GACTTGGGAG GAGAGCCAAT CACAGGCAGT CAGTACTTTG GGAATGGCCG	2460
CGTGACAGAA TTCAAGTATG GTGCCAACT GGGGACGGTG ATCCGGAAGT GGAATGGAGA	2520
GAAGATGGCC TACTTAAAGA ACTGGGGAGA AGGCTGGGGC TTTGTGCCTT CTGACAGAGC	2580
CCTGGTGTTT GTGGATAACC ACGACAACCA GCGGGGCGAC GGGGCAGGCG GAGCTTCCAT	2640
TCTTACTTTC TGGGATGCCA GGCTTTATAA AATGGCGGTT GGTTCATGC TCGCTCATCC	2700
GTACGGGTTC ACACGGGTGA TGTCAAGTTA TCGTTGGCCA AGATATTTG AAAACGGAGT	2760
GGATGTTAAC GACTGGGTGG GACCACCAAG TAACTCGGAC GGATCGACGA AGTCCGTTAC	2820
AATCAACGCA GACACTACCT GTGGCAATGA CTGGGTCTGC GAACATCGCT GGCACAAAT	2880
AAGGAACATG GTTATCTTCC GTAATGTGGT AGACGGTCAG CCTTCTCAA ACTGGTGGGA	2940
CAACGGGAGC AATCAAGTAG CTTTCGGTCG CGGCGACAGA GGCTTCATTG TCTTTAATAA	3000
TGATGACTGG TATATGAATG TCGATTGCA AACTGGTCTG CCTGCTGGAA CCTACTGCGA	3060
TGTTATTCTT GGACAAAAGG AAGGCAGTGC GTGTACTGGA AAGCAGGTGT ACGTTTCCTC	3120
GGATGGAAAG GCCAATTTCC AGATTAGTAA CAGCGATGAA GATCCATTTG TTGCAATTCA	3180
CGTTGATGCC AAGTTATAAG CTTGAGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA	3240
TTCGGCTTGT CGACATCTAG GCGGCCAAT TCCGCCCCCTC TCCCCCCCCC CCCTAACGTT	3300
ACTGGCCGAA GCCGCTTGGA ATAAGGCCGG TGTGTGTTG TCTATATGTG ATTTTCCACC	3360
ATATTGCCGT CTTTGGCAA TGTGAGGGCC CGGAAACCTG GCCCTGTCTT CTTGACGAGC	3420
ATTCCTAGGG GTCTTTCCCC TCTCGCCAAA GGAATGCAAG GTCTGTTGAA TGTGCGTAAG	3480
GAAGCAGTTC CTCTGGAAGC TTCTGAAGA CAAACAACGT CTGTAGCGAC CCTTTGCAGG	3540
CAGCGGAACC CCCACCTGG CGACAGGTGC CTCTGCGGCC AAAAGCCACG TGTATAAGAT	3600
ACACCTGCAA AGGCGGCACA ACCCCAGTGC CACGTTGTGA GTTGGATAGT TGTGGAAAGA	3660
GTCAAATGGC TCTCCTCAAG CGTAGTCAAC AAGGGGCTGA AGGATGCCCA GAAGGTACCC	3720

CATTGTATGG GAATCTGATC TGGGGCCTCG GTGCACATGC TTTACATGTG TTTAGTCGAG	3780
GTAAAAAAG CTCTAGGCCC CCCGAACCAC GGGGACGTGG TTTTCCTTTG AAAAACACGA	3840
TGATAAGCTT GCCACAACCC AACAGCGTC AACAGCGTGC CGCAGATCCC GGGCAATGAG	3900
ATATGAAAA GCCTGAACTC ACCGCGACGT CTGTCGAGAA GTTTCTGATC GAAAAGTTCTG	3960
ACAGCGTCTC CGACCTGATG CAGCTCTCGG AGGGCGAAGA ATCTCGTGCT TTCAGCTTCG	4020
ATGTAGGAGG GCGTGGATAT GTCCTGCGGG TAAATAGCTG CGCCGATGGT TTCTACAAAG	4080
ATCGTTATGT TTATCGGCAC TTTGCATCGG CCGCGCTCCC GATTCCGGAA GTGCTTGACA	4140
TTGGGGAATT CAGCGAGAGC CTGACCTATT GCATCTCCCG CCGTGCACAG GGTGTCACGT	4200
TGCAAGACCT GCCTGAAACC GAACTGCCCC CTGTTCTGCA GCCGGTCGCG GAGGCCATGG	4260
ATGCGATCGC TGCGGCCGAT CTTAGCCAGA CGAGCGGGTT CGGCCCATTC GGACCGCAAG	4320
GAATCGGTCA ATACACTACA TGGCGTGATT TCATATGCGC GATTGCTGAT CCCCATGTGT	4380
ATCACTGGCA AACTGTGATG GACGACACCG TCAGTGCGTC CGTCGCGCAG GCTCTCGATG	4440
AGCTGATGCT TTGGGCCGAG GACTGCCCCG AAGTCCGGCA CCTCGTGAC GCGGATTTCTG	4500
GCTCCAACAA TGTCTGACG GACAATGGCC GCATAACAGC GGTCATTGAC TGGAGCGAGG	4560
CGATGTTCTCGG GGATTCCCAA TACGAGGTCG CCAACATCTT CTTCTGGAGG CCGTGGTTGG	4620
CTTGATGGA GCAGCAGACG CGTACTTCG AGCGGAGGCA TCCGGAGCTT GCAGGATCGC	4680
CGCGGCTCCG GCGGTATATG CTCGCGATTG GTCTTGACCA ACTCTATCAG AGCTTGTTG	4740
ACGGCAATTT CGATGATGCA GCTTGGGCGC AGGGTCGATG CGACGCAATC GTCCGATCCG	4800
GAGCCGGGAC TGTGCGGCGT ACACAAATCG CCCGAGAAG CGCGGCCGTC TGGACCGATG	4860
GCTGTGTAGA AGTACTCGCC GATAGTGGA ACCGACGCCC CAGCACTCGT CCGAGGGCAA	4920
AGGAATAGGG GAGATGGGGG AGGCTAACTG AAACACGGAA GGGCCCGCGG GACTCTGGGG	4980
TTGATAAAA TAAAAGATTT TATTTAGTCT CCAGAAAAAG GGGGGAATGA AAGACCCAC	5040
CTGTAGGTTT GGCAAGCTAG CTTAAGTAAC GCCATTTTGC AAGGCATGGA AAAATACATA	5100
ACTGAGAATA GAGAAGTTCA GATCAAGGTC AGGAACAGAT GGAACAGCTG AATATGGGCC	5160
AAACAGGATA TCTGTGGTAA GCAGTTCCTG CCCCGGCTCA GGGCCAAGAA CAGATGGAAC	5220
AGCTGAATAT GGGCCAAACA GGATATCTGT GGTAAGCAGT TCCTGCCCCG GCTCAGGGCC	5280
AAGAACAGAT GGTCCCCAGA TGCGGTCCAG CCCTCAGCAG TTTCTAGAGA ACCATCAGAT	5340
GTTTCCAGGG TGCCCCAAGG ACCTGAAATG ACCCTGTGCC TTATTTGAAC TAACCAATCA	5400

GTTTCGCTTCT	CGCTTCTGTT	CGCGCGCTTC	TGCTCCCCGA	GCTCAATAAA	AGAGCCCACA	5460
ACCCCTCACT	CGGGGCGCCA	GTCCTCCGAT	TGACTGAGTC	GCCCCGGTAC	CCGTGTATCC	5520
AATAAACCT	CTTGAGTTG	CATCCGACTT	GTGGTCTCGC	TGTTCTTGG	GAGGGTCTCC	5580
TCTGAGTGAT	TGACTACCCG	TCAGCGGGG	TCTTTCATTT	GGGGGCTCGT	CCGGGATCGG	5640
GAGACCCCTG	CCCAGGGACC	ACCGACCCAC	CACCGGGAGG	TAAGCTGGCT	GCCTCGCGCG	5700
TTTCGGTGAT	GACGGTGAAA	ACCTCTGACA	CATGCAGCTC	CCGGAGACGG	TCACAGCTTG	5760
TCTGTAAGCG	GATGCCGGGA	GCAGACAAGC	CCGTCAGGGC	GCGTCAGCGG	GTGTTGGCGG	5820
GTGTCGGGGC	GCAGCCATGA	CCCAGTCACG	TAGCGATAGC	GGAGTGATA	CTGGCTTAAC	5880
TATGCGGCAT	CAGAGCAGAT	TGTACTGAGA	GTGCACCATA	TGCGGTGTGA	AATACCGCAC	5940
AGATGCGTAA	GGAGAAAATA	CCGCATCAGG	CGCTCTTCCG	CTTCCTCGCT	CACTGACTCG	6000
CTGCGCTCGG	TCGTTCCGCT	GCGGCGAGCG	GTATCAGCTC	ACTCAAAGGC	GGTAATACGG	6060
TTATCCACAG	AATCAGGGGA	TAACGCAGGA	AAGAACATGT	GAGCAAAAGG	CCAGCAAAAG	6120
GCCAGGAACC	GTAAAAAGGC	CGCGTTGCTG	GCGTTTTTCC	ATAGGCTCCG	CCCCCTGAC	6180
GAGCATCACA	AAAATCGACG	CTCAAGTCAG	AGGTGGCGAA	ACCCGACAGG	ACTATAAAGA	6240
TACCAGGCGT	TTCCCCCTGG	AAGCTCCCTC	GTGCGCTCTC	CTGTTCCGAC	CCTGCCGCTT	6300
ACCGGATACC	TGTCCGCCTT	TCTCCCTTCG	GGAAGCGTGG	CGCTTCTCTCA	TAGCTCACGC	6360
TGTAGGTATC	TCAGTTCGGT	GTAGGTCGTT	CGCTCCAAGC	TGGGCTGTGT	GCACGAACCC	6420
CCCGTTCAGC	CCGACCGCTG	CGCCTTATCC	GGTAACTATC	GTCTTGAGTC	CAACCCGGTA	6480
AGACACGACT	TATCGCCACT	GGCAGCAGCC	ACTGGTAACA	GGATTAGCAG	AGCGAGGTAT	6540
GTAGGCGGTG	CTACAGAGTT	CTTGAAGTGG	TGGCCTAACT	ACGGCTACAC	TAGAAGGACA	6600
GTATTTGGTA	TCTGCGCTCT	GCTGAAGCCA	GTTACCTTCG	GAAAAAGAGT	TGGTAGCTCT	6660
TGATCCGGCA	AACAAACCAC	CGCTGGTAGC	GGTGGTTTTT	TGTTTGCAA	GCAGCAGATT	6720
ACGCGCAGAA	AAAAAGGATC	TCAAGAAGAT	CCTTTGATCT	TTTCTACGGG	GTCTGACGCT	6780
CAGTGGAACG	AAAATCAGC	TTAAGGGATT	TTGGTCATGA	GATTATCAAA	AAGGATCTTC	6840
ACCTAGATCC	TTTTAAATTA	AAAATGAAGT	TTTAAATCAA	TCTAAAGTAT	ATATGAGTAA	6900
ACTTGGTCTG	ACAGTTACCA	ATGCTTAATC	AGTGAGGCAC	CTATCTCAGC	GATCTGTCTA	6960
TTTCGTTTCAT	CCATAGTTGC	CTGACTCCCC	GTCGTGTAGA	TAAGTACGAT	ACGGGAGGGC	7020
TTACCATCTG	GCCCCAGTGC	TGCAATGATA	CCGCGAGACC	CACGCTCACC	GGCTCCAGAT	7080

TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA	7140
TCCGCCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT	7200
AATAGTTTGC GCAACGTTGT TGCCATTGCT GCAGGCATCG TGGTGTACG CTCGTCGTTT	7260
GGTATGGCTT CATTAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCATG	7320
TTGTGCAAAA AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC	7380
GCAGTGTTAT CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC	7440
GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGATG	7500
CGGCGACCGA GTTGCTCTTG CCCGGCGTCA ACACGGGATA ATACCGCGCC ACATAGCAGA	7560
ACTTTAAAAG TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACTCTC AAGGATCTTA	7620
CCGCTGTTGA GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT	7680
TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAG	7740
GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTTCA ATATTATTGA	7800
AGCATTTATC AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT	7860
AAACAAATAG GGGTTCCGCG CACATTTCCC CGAAAAGTGC CACCTGACGT CTAAGAAACC	7920
ATTATTATCA TGACATTAACT CTATAAAAAT AGGCGTATCA CGAGGCCCTT TCGTCTTCAA	7980

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7311 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GAATTCATAC CAGATCACCG AAAACTGTCC TCCAAATGTG TCCCCCTCAC ACTCCCAAAT	60
TCGCGGGCTT CTGCCTCTTA GACCACTCTA CCCTATTCCC CACACTCACC GGAGCCAAAG	120
CCGCGGCCCT TCCGTTTCTT TGCTTTTGAA AGACCCACCG CGTAGGTGGC AAGCTAGCTT	180
AAGTAACGCC ACTTTGCAAG GCATGGAAAA ATACATAACT GAGAATAGAA AAGTTCAGAT	240
CAAGGTCAGG AACAAAGAAA CAGCTGAATA CCAAACAGGA TATCTGTGGT AAGCGGTTCC	300

TGCCCCGGCT CAGGGCCAAG AACAGATGAG ACAGCTGAGT GATGGGCCAA ACAGGATATC	360
TGTGGTAAGC AGTTCCTGCC CCGGCTCGGG GCCAAGAACA GATGGTCCCC AGATGCGGTC	420
CAGCCCTCAG CAGTTTCTAG TGAATCATCA GATGTTTCCA GGGTGCCCCA AGGACCTGAA	480
AATGACCCTG TACCTTATTT GAACTAACCA ATCAGTTTCG TTCTCGCTTC TGTTCGCGCG	540
CTTCCGCTCT CCGAGCTCAA TAAAAGAGCC CACAACCCCT CACTCGGCGC GCCAGTCTTC	600
CGATAGACTG CGTCGCCCCG GTACCCGTAT TCCCAATAAA GCCTCTTGCT GTTTCATCC	660
GAATCGTGGT CTCGCTGTTT CTGGGAGGG TCTCCTCTGA GTGATTGACT ACCCACGACG	720
GGGGTCTTTC ATTTGGGGGC TCGTCCGGGA TTTGGAGACC CCTGCCCAGG GACCACCGAC	780
CCACCACCGG GAGGTAAGCT GGCCAGCAAC TTATCTGTGT CTGTCCGATT GTCTAGTGTC	840
TATGTTTGAT GTTATGCGCC TCGTCTGTA CTAGTTAGCT AACTAGCTCT GTATCTGGCG	900
GACCCGTGGT GGAACGACG AGTTCTGAAC ACCCGGCCGC AACCTGGGA GACGTCCAG	960
GGACTTTGGG GGCCGTTTTT GTGGCCCGAC CTGAGGAAGG GAGTCGATGT GGAATCCGAC	1020
CCCGTCAGGA TATGTGGTTC TGGTAGGAGA CGAGAACCTA AAACAGTTCC CGCCTCCGTC	1080
TGAATTTTGT CTTTCGGTTT GGAACCGAAG CCGCGCGTCT TGTCTGCTGC AGCGCTGCAG	1140
CATCGTTCTG TGTGTCTCT GTCTGACTGT GTTCTGTAT TTGTCTGAAA ATTAGGGCCA	1200
GACTGTTACC ACTCCCTTAA GTTTGACCTT AGGTCACTGG AAAGATGTCG AGCGGATCGC	1260
TCACAACCAG TCGGTAGATG TCAAGAAGAG ACGTTGGGTT ACCTTCTGCT CTGCAGAATG	1320
GCCAACCTTT AACGTCGGAT GGCCGCGAGA CGGCACCTTT AACCGAGACC TCATCACCCA	1380
GGTTAAGATC AAGGTCTTTT CACCTGGCCC GCATGGACAC CCAGACCAGG TCCCCTACAT	1440
CGTGACCTGG GAAGCCTTGG CTTTGGACCC CCCTCCCTGG GTCAAGCCCT TTGTACACCC	1500
TAAGCCTCCG CCTCCTCTTC CTCCATCCGC CCCGTCTCTC CCCCTTGAAC CTCCTCGTTC	1560
GACCCCGCCT CGATCCTCCC TTTATCCAGC CCTCACTCCT TCTCTAGGCG CCGGAATTCC	1620
GATCTGATCA AGAGACAGGA TGAGGATCGT TTCGCATGAT TGAACAAGAT GGATTGCACG	1680
CAGGTTCTCC GGCCGCTTGG GTGGAGAGGC TATTCGGCTA TGAAGGGCA CAACAGACAA	1740
TCGGCTGCTC TGATGCCGCC GTGTTCCGGC TGTCAGCGCA GGGGCGCCCG GTTCTTTTGT	1800
TCAAGACCGA CCTGTCCGGT GCCCTGAATG AACTGCAGGA CGAGGCAGCG CGGCTATCGT	1860
GGCTGGCCAC GACGGGCGTT CCTTGCGCAG CTGTGCTCGA CGTTGTCACT GAAGCGGGAA	1920
GGGACTGGCT GCTATTGGGC GAAGTGCCGG GGCAGGATCT CCTGTCTCT CACCTTGCTC	1980

CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG GCTGCATACG CTTGATCCGG	2040
CTACCTGCCC ATTCGACCAC CAAGCGAAAC ATCGCATCGA GCGAGCACGT ACTCGGATGG	2100
AAGCCGGTCT TGTGATCAG GATGATCTGG ACGAAGAGCA TCAGGGGCTC GCGCCAGCCG	2160
AACTGTTTCG CAGGCTCAAG GCGCGCATGC CCGACGGCGA GGATCTCGTC GTGACCCATG	2220
GCGATGCCTG CTTGCCGAAT ATCATGGTGG AAAATGGCCG CTTTCTGGA TTCATCGACT	2280
GTGGCCGGCT GGGTGTGGCG GACCGCTATC AGGACATAGC GTTGGCTACC CGTGATATTG	2340
CTGAAGAGCT TGGCGGCGAA TGGGCTGACC GCTTCTCGT GCTTTACGGT ATCGCCGCTC	2400
CCGATTCGCA GCGCATCGCC TTCTATCGCC TTCTTGACGA GTTCTTCTGA GCGGGACTCT	2460
GGGGTTCGAA ATGACCGACC AAGCGACGCC CAACCTGCCA TCACGAGATT TCGATTCCAC	2520
CGCCGCCTTC TATGAAAGGT TGGGCTTCGG AATCGTTTTTC CGGGACGCCG GCTGGATGAT	2580
CCTCCAGCGC GGGGATCTCA TGCTGGAGTT CTTCGCCCAC CCCGGGCTCG ATCCCCTCGC	2640
GAGTTGGTTC AGCTGCTGCC TGAGGCTGGA CGACCTCGCG GAGTTCTACC GGCAGTGCAA	2700
ATCCGTCGCG ATCCAGGAAA CCAGCAGCGG CTATCCGCGC ATCCATGCCC CCGAACTGCA	2760
GGAGTGGGGA GGCACGATGG CCGCTTTGGT CGAGGCGGAT CCGGGCAGAA ATGGTTGAAC	2820
TCCCAGAGT GTCCTACACC TAGGGGAGAA GCAGCCAAGG GGTGTGTTCC CACCAAGGAC	2880
GACCCGTCTG CGCACAAACG GATGAGCCCA TCAGACAAAG ACATATTCAT TCTCTGCTGC	2940
AAACTTGGCA TAGCTCTGCT TTGCCTGGGG CTATTGGGGG AAGTTGCGGT TCGTGCTCGC	3000
AGGGCTCTCA CCCTTGACTC TTTTAATAGC TCTTCTGTGC AAGATTACAA TCTAAACAAT	3060
TCGGAGAACT CGACCTTCCT CCTGAGGCAA GGACCACAGC CAACTTCCTC TTACAAGCCG	3120
CATCGATTTT GTCCTTCAGA AATAGAAATA AGAATGCTTG CTAAAAATTA TATTTTTACC	3180
AATAAGACCA ATCCAATAGG TAGATTATTA GTTACTATGT TAAGAAATGA ATCATTATCT	3240
TTTAGTACTA TTTTACTCA AATTCAGAAG TTAGAAATGG GAATAGAAAA TAGAAAGAGA	3300
CGCTCAACCT CAATTGAAGA ACAGGTGCAA GGACTATTGA CCACAGGCCT AGAAGTAAAA	3360
AAGGGAAAAA AGAGTGTTTT TGTCAAATA GGAGACAGGT GGTGGCAACC AGGGACTTAT	3420
AGGGGACCTT ACATCTACAG ACCAACAGAT GCCCCCTTAC CATATACAGG AAGATATGAC	3480
TTAAATTGGG ATAGGTGGGT TACAGTCAAT GGCTATAAAG TGTATATAG ATCCCTCCCT	3540
TTTCGTGAAA GACTCGCCAG AGCTAGACCT CCTTGGTGTA TGTGTCTCA AGAAGAAAAA	3600
GACGACATGA AACAACAGGT ACATGATTAT ATTTATCTAG GAACAGGAAT GCACTTTTGG	3660

GGAAAGATTT TCCATACCAA GGAGGGGACA GTGGCTGGAC TAATAGAACA TTATTCTGCA	3720
AAAACATCATG GCATGAGTTA TTATGAATAG CCTTTATTGG CCCAACCTTG CGGTTCCCAG	3780
GGCTTAAGTA AGTTTTTGGT TACAAACTGT TCTTAAAACG AGGATGTGAG ACAAGTGGTT	3840
TCCTGACTTG GTTTGGTATC AAAGGTTCTG ATCTGAGCTC TGAGTGTCTT ATTTTCCTAT	3900
GTTCTTTTGG AATTTATCCA AATCTTATGT AAATGCTTAT GTAAACCAAG ATATAAAGA	3960
GTGCTGATTT TTTGAGTAAA CTGCAACAG TCCTAACATT CACCTCTTGT GTGTTTGTGT	4020
CTGTTTCGCCA TCCCGTCTCC GCTCGTCACT TATCCTTCAC TTTCCAGAGG GTCCCCCGC	4080
AGACCCCGGC GACCCTCAGG TCGGCCGACT GCGGCAGCTG GCGCCCGAAC AGGGACCCTC	4140
GGATAAGTGA CCCTTGCTCT TATTTCTACT ATTTGGTGTT TGTCTTGAT TGTCTCTTC	4200
TTGTCTGGCT ATCATCACAA GAGCGGAACG GACTCACCAT AGGGACCAAG CTTGTCGACA	4260
TTTCTGCAGA TATCCATCAC ACTGGCGGCC GCTCGAGCAT GCATCTAGAA CATCGATAAA	4320
ATAAAAGATT TTATTAGTC TCCAGAAAAA GGGGGGAATG AAAGACCCCA CCTGTAGGTT	4380
TGGCAAGCTA GCTTAAGTAA CGCCATTTTG CAAGGCATGG AAAAATACAT AACTGAGAAT	4440
AGAGAAGTTC AGATCAAGGT CAGGAACAGA TGGAACAGCT GAATATGGGC CAAACAGGAT	4500
ATCTGTGGTA AGCAGTTCCT GCCCCGGCTC AGGGCCAAGA ACAGATGGAA CAGCTGAATA	4560
TGGGCCAAAC AGGATATCTG TGGTAAGCAG TTCCTGCCCC GGCTCAGGGC CAAGAACAGA	4620
TGGTCCCCAG ATGCGGTCCA GCCCTCAGCA GTTCTAGAG AACCATCAGA TGTTTCCAGG	4680
GTGCCCCAAG GACCTGAAAT GACCCTGTGC CTTATTTGAA CTAACCAATC AGTTCGCTTC	4740
TCGCTTCTGT TCGCGCGCTT CTGCTCCCCG AGCTCAATAA AAGAGCCCAC AACCCTCAC	4800
TCGGGGCGCC AGTCCTCCGA TTGACTGAGT CGCCCGGTA CCCGTGTATC CAATAAACCC	4860
TCTTGCAAGT GCATCCGACT TGTGGTCTCG CTGTTCCCTG GGAGGGTCTC CTCTGAGTGA	4920
TTGACTACCC GTCAGCGGGG GTCTTTCATT TGGGGGCTCG TCCGGGATCG GGAGACCCT	4980
GCCCAGGGAC CACCGACCCA CCACCGGGAG GTAAGCTGGC TGCCTCGCGC GTTTCGGTGA	5040
TGACGGTGAA AACCTCTGAC ACATGCAGCT CCCGGAGACG GTCACAGCTT GTCTGTAAGC	5100
GGATCCCGG AGCAGACAAG CCCGTCAGGG CGCGTCAGCG GGTGTTGGCG GGTGTCGGGG	5160
CGCAGCCATG ACCCAGTCAC GTAGCGATAG CGGAGTGTAT ACTGGCTTAA CTATGCGGCA	5220
TCAGAGCAGA TTGTACTGAG AGTGCACCAT ATGCGGTGTG AAATACCGCA CAGATGCGTA	5280
AGGAGAAAAT ACCGCATCAG GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG	5340

GTCGTTTCGGC	TGCGGCGAGC	GGTATCAGCT	CACTCAAAGG	CGGTAATACG	GTTATCCACA	5400
GAATCAGGGG	ATAACGCAGG	AAAGAACATG	TGAGCAAAAG	GCCAGCAAAA	GGCCAGGAAC	5460
CGTAAAAAGG	CCGCGTTGCT	GGCGTTTTTC	CATAGGCTCC	GCCCCCTGA	CGAGCATCAC	5520
AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA	AACCCGACAG	GACTATAAAG	ATACCAGGCG	5580
TTTCCCCCTG	GAAGCTCCCT	CGTGCGCTCT	CCTGTTCCGA	CCCTGCCGCT	TACCGGATAC	5640
CTGTCCGCCT	TTCTCCCTTC	GGGAAGCGTG	GCGCTTTCTC	ATAGCTCACG	CTGTAGGTAT	5700
CTCAGTTCGG	TGTAGGTCGT	TCGCTCCAAG	CTGGGCTGTG	TGCACGAACC	CCCCGTTTCA	5760
CCCGACCGCT	GCGCCTTATC	CGGTAACTAT	CGTCTTGAGT	CCAACCCGGT	AAGACACGAC	5820
TTATCGCCAC	TGGCAGCAGC	CACTGGTAAC	AGGATTAGCA	GAGCGAGGTA	TGTAGGCGGT	5880
GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	TACGGCTACA	CTAGAAGGAC	AGTATTTGGT	5940
ATCTGCGCTC	TGCTGAAGCC	AGTTACCTTC	GGAAAAGAG	TTGGTAGCTC	TTGATCCGGC	6000
AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTGTTTGCA	AGCAGCAGAT	TACGCGCAGA	6060
AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG	GGTCTGACGC	TCAGTGAAC	6120
GAAAACTCAC	GTTAAGGGAT	TTTGGTCATG	AGATTATCAA	AAAGGATCTT	CACCTAGATC	6180
CTTTTAAATT	AAAAATGAAG	TTTTAAATCA	ATCTAAAGTA	TATATGAGTA	AACTTGGTCT	6240
GACAGTTACC	AATGCTTAAT	CAGTGAGGCA	CCTATCTCAG	CGATCTGTCT	ATTTCGTTCA	6300
TCCATAGTTG	CCTGACTCCC	CGTCGTGTAG	ATAACTACGA	TACGGGAGGG	CTTACCATCT	6360
GGCCCCAGTG	CTGCAATGAT	ACCGCGAGAC	CCACGCTCAC	CGGCTCCAGA	TTTATCAGCA	6420
ATAAACCAGC	CAGCCGGAAG	GGCCGAGCGC	AGAAGTGGTC	CTGCAACTTT	ATCCGCCTCC	6480
ATCCAGTCTA	TTAATTGTTG	CCGGGAAGCT	AGAGTAAGTA	GTTCGCCAGT	TAATAGTTTG	6540
CGCAACGTTG	TTGCCATTGC	TGCAGGCATC	GTGGTGTAC	GCTCGTCGTT	TGGTATGGCT	6600
TCATTCAGCT	CCGGTTCCCA	ACGATCAAGG	CGAGTTACAT	GATCCCCCAT	GTTGTGCAAA	6660
AAAGCGGTTA	GCTCCTTCGG	TCCTCCGATC	GTTGTCAGAA	GTAAGTTGGC	CGCAGTGTTA	6720
TCACTCATGG	TTATGGCAGC	ACTGCATAAT	TCTCTTACTG	TCATGCCATC	CGTAAGATGC	6780
TTTTCTGTGA	CTGGTGAGTA	CTCAACCAAG	TCATTCTGAG	AATAGTGTAT	GCGGCGACCG	6840
AGTTGCTCTT	CCCCGGCGTC	AACACGGGAT	AATACCGCGC	CACATAGCAG	AACTTTAAAA	6900
GTGCTCATCA	TTGAAAACG	TTCTTCGGGG	CGAAAACCTCT	CAAGGATCTT	ACCGCTGTTG	6960
AGATCCAGTT	CGATGTAACC	CACTCGTGCA	CCCAACTGAT	CTTCAGCATC	TTTTACTTTC	7020

ACCAGCGTTT CTGGGTGAGC AAAACAGGA AGGCAAAATG CCGCAAAAAA GGAATAAGG	7080
GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG AAGCATTTAT	7140
CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA	7200
GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTGACG TCTAAGAAAC CATTATTATC	7260
ATGACATTAA CCTATAAAAA TAGGCGTATC ACGAGGCCCT TTCGTCTTCA A	7311

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7885 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GAATTCATAC CAGATCACCG AAAACTGTCC TCCAAATGTG TCCCCCTCAC ACTCCCAAAT	60
TCGCGGGCTT CTGCCTCTTA GACCACTCTA CCCTATTCCC CACACTCACC GGAGCCAAAG	120
CCGCGGCCCT TCCGTTTCTT TGCTTTTGAA AGACCCACCC CGTAGGTGGC AAGCTAGCTT	180
AAGTAACGCC ACTTTGCAAG GCATGGAAAA ATACATAACT GAGAATAGAA AAGTTCAGAT	240
CAAGGTCAGG AACAAAGAAA CAGCTGAATA CCAAACAGGA TATCTGTGGT AAGCGGTTCC	300
TGCCCCGGCT CAGGGCCAAG AACAGATGAG ACAGCTGAGT GATGGGCCAA ACAGGATATC	360
TGTGGTAAGC AGTTCCTGCC CCGGCTCGGG GCCAAGAACA GATGGTCCCC AGATGCGGTC	420
CAGCCCTCAG CAGTTTCTAG TGAATCATCA GATGTTTCCA GGGTGCCCCA AGGACCTGAA	480
AATGACCCTG TACCTTATTT GAACTAACCA ATCAGTTCGC TTCTCGCTTC TGTTGCGCGC	540
CTTCCGCTCT CCGAGCTCAA TAAAGAGCC CACAACCCCT CACTCGGCGC GCCAGTCTTC	600
CGATAGACTG CGTCGCCCCG GTACCCGTAT TCCCAATAAA GCCTCTTGCT GTTTGCATCC	660
GAATCGTGGT CTCGCTGTTC CTTGGGAGGG TCTCCTCTGA GTGATTGACT ACCCAGCAGC	720
GGGGTCTTTC ATTTGGGGGC TCGTCCGGGA TTTGGAGACC CCTGCCCAGG GACCACCGAC	780
CCACCACCGG GAGGTAAGCT GGCCAGCAAC TTATCTGTGT CTGTCCGATT GTCTAGTGTC	840
TATGTTTGAT GTTATGCGCC TCGTCTGTA CTAGTTAGCT AACTAGCTCT GTATCTGGCG	900
GACCCGTGGT GGAAGTGACG AGTTCTGAAC ACCCGGCCGC AACCCCTGGGA GACGTCCCAG	960

GGACTTTGGG	GGCCGTTTTT	GTGGCCCGAC	CTGAGGAAGG	GAGTCGATGT	GGAATCCGAC	1020
CCCGTCAGGA	TATGTGGTTC	TGGTAGGAGA	CGAGAACCTA	AAACAGTTCC	CGCCTCCGTC	1080
TGAATTTTTG	CTTTCGGTTT	GGAACCGAAG	CCGCGCGTCT	TGTCTGCTGC	AGCGCTGCAG	1140
CATCGTTCTG	TGTTGTCTCT	GTCTGACTGT	GTTTCTGTAT	TTGTCTGAAA	ATTAGGGCCA	1200
GA CTGTTACC	ACTCCCTTAA	GTTTGACCTT	AGGTCACTGG	AAAGATGTCG	AGCGGATCGC	1260
TCACAACCAG	TCGGTAGATG	TCAAGAAGAG	ACGTTGGGTT	ACCTTCTGCT	CTGCAGAATG	1320
GCCAACCTTT	AACGTCGGAT	GGCCGCGAGA	CGGCACCTTT	AACCGAGACC	TCATCACCCA	1380
GGTTAAGATC	AAGGTCTTTT	CACCTGGCCC	GCATGGACAC	CCAGACCAGG	TCCCCTACAT	1440
CGTGACCTGG	GAAGCCTTGG	CTTTTGACCC	CCCTCCCTGG	GTCAAGCCCT	TTGTACACCC	1500
TAAGCCTCCG	CCTCCTCTTC	CTCCATCCGC	CCCGTCTCTC	CCCCTGAAC	CTCCTCGTTC	1560
GACCCCGCCT	CGATCCTCCC	TTTATCCAGC	CCTCACTCCT	TCTCTAGGCG	CCGGAATTCC	1620
GATCTGATCA	AGAGACAGGA	TGAGGATCGT	TTGCGATGAT	TGAACAAGAT	GGATTGCACG	1680
CAGGTTCTCC	GGCCGCTTGG	GTGGAGAGGC	TATTCGGCTA	TGACTGGGCA	CAACAGACAA	1740
TCGGCTGCTC	TGATGCCGCC	GTGTTCCGGC	TGTCAGCGCA	GGGGCGCCCG	GTTCTTTTTG	1800
TCAAGACCGA	CCTGTCCGGT	GCCCTGAATG	AACTGCAGGA	CGAGGCAGCG	CGGCTATCGT	1860
GGCTGGCCAC	GACGGGCGTT	CCTTGCGCAG	CTGTGCTCGA	CGTTGTCACT	GAAGCGGGAA	1920
GGGACTGGCT	GCTATTGGGC	GAAGTGCCGG	GGCAGGATCT	CCTGTCACTC	CACCTTGCTC	1980
CTGCCGAGAA	AGTATCCATC	ATGGCTGATG	CAATGCGGCG	GCTGCATACG	CTTGATCCGG	2040
CTACCTGCCC	ATTCGACCAC	CAAGCGAAAC	ATCGCATCGA	GCGAGCACGT	ACTCGGATGG	2100
AAGCCGGTCT	TGTCGATCAG	GATGATCTGG	ACGAAGAGCA	TCAGGGGCTC	GCGCCAGCCG	2160
AACTGTTTCG	CAGGCTCAAG	GCGCGCATGC	CCGACGGCGA	GGATCTCGTC	GTGACCCATG	2220
GCGATGCCTG	CTTGCCGAAT	ATCATGGTGG	AAAATGGCCG	CTTTTCTGGA	TTCATCGACT	2280
GTGGCCGGCT	GGGTGTGGCG	GACCGCTATC	AGGACATAGC	GTTGGCTACC	CGTGATATTG	2340
CTGAAGAGCT	TGGCGGCGAA	TGGGCTGACC	GCTTCCTCGT	GCTTTACGGT	ATCGCCGCTC	2400
CCGATTGCGA	GCGCATCGCC	TTCTATCGCC	TTCTTGACGA	GTTCTTCTGA	GCGGGACTCT	2460
GGGGTTCGAA	ATGACCGACC	AAGCGACGCC	CAACCTGCCA	TCACGAGATT	TCGATTCCAC	2520
CGCCGCTTTC	TATGAAAGGT	TGGGCTTCGG	AATCGTTTTT	CGGGACGCCG	GCTGGATGAT	2580
CCTCCAGCGC	GGGGATCTCA	TGCTGGAGTT	CTTCGCCCCAC	CCCGGGCTCG	ATCCCCCTCGC	2640

GAGTTGGTTC AGCTGCTGCC TGAGGCTGGA CGACCTCGCG GAGTTCTACC GGCAGTGCAA	2700
ATCCGTCGGC ATCCAGGAAA CCAGCAGCGG CTATCCGCGC ATCCATGCCC CCGAACTGCA	2760
GGAGTGGGGA GGCACGATGG CCGCTTTGGT CGAGGCGGAT CCGGGCAGAA ATGTTGAAC	2820
TCCCAGAGT GTCCTACACC TAGGGGAGAA GCAGCCAAGG GGTGTGTTCC CACCAAGGAC	2880
GACCCGTCTG CGCACAAACG GATGAGCCCA TCAGACAAAG ACATATTCAT TCTCTGCTGC	2940
AAACTTGGCA TAGCTCTGCT TTGCCTGGGG CTATTGGGGG AAGTTGCGGT TCGTGCTCGC	3000
AGGGCTCTCA CCCTTGACTC TTTTAATAGC TCTTCTGTGC AAGATTACAA TCTAAACAAT	3060
TCGGAGAACT CGACCTTCCT CCTGAGGCAA GGACCACAGC CAACTTCCTC TTACAAGCCG	3120
CATCGATTTT GTCCTTCAGA AATAGAAATA AGAATGCTTG CTAAAAATTA TATTTTTACC	3180
AATAAGACCA ATCCAATAGG TAGATTATTA GTTACTATGT TAAGAAATGA ATCATTATCT	3240
TTTAGTACTA TTTTACTCA AATTCAGAAG TTAGAAATGG GAATAGAAAA TAGAAAGAGA	3300
CGCTCAACCT CAATTGAAGA ACAGGTGCAA GGACTATTGA CCACAGGCCT AGAAGTAAAA	3360
AAGGGAAAAA AGAGTGTTTT TGTCAAATA GGAGACAGGT GGTGGCAACC AGGGACTTAT	3420
AGGGGACCTT ACATCTACAG ACCAACAGAT GCCCCCTTAC CATATACAGG AAGATATGAC	3480
TTAAATTGGG ATAGTGGGT TACAGTCAAT GGCTATAAAG TGTATATAG ATCCCTCCCT	3540
TTTCGTGAAA GACTCGCCAG AGCTAGACCT CCTTGGTGTA TGTGTCTCA AGAAGAAAAA	3600
GACGACATGA AACAACAGGT ACATGATTAT ATTTATCTAG GAACAGGAAT GCACTTTTGG	3660
GGAAAGATTT TCCATACCAA GGAGGGGACA GTGGCTGGAC TAATAGAACA TTATTCTGCA	3720
AAAATCATG GCATGAGTTA TTATGAATAG CCTTTATTGG CCCAACCTTG CGGTTCCAG	3780
GGCTTAAGTA AGTTTTTGGT TACAACTGT TCTTAAACG AGGATGTGAG ACAAGTGGTT	3840
TCCTGACTTG GTTTGGTATC AAAGGTTCTG ATCTGAGCTC TGAGTGTCTT ATTTTCCTAT	3900
GTTCTTTTGG AATTATCCA AATCTTATGT AAATGCTTAT GTAAACCAAG ATATAAAGA	3960
GTGCTGATTT TTTGAGTAA CTTGCAACAG TCCTAACATT CACCTCTTGT GTGTTTGTGT	4020
CTGTTCCCA TCCCGTCTCC GCTCGTCACT TATCCTTCAC TTTCCAGAGG GTCCCCCGC	4080
AGACCCCGGC GACCCCTCAGG TCGGCCGACT GCGGCAGCTG GCGCCGAAC AGGGACCCTC	4140
GGATAAGTGA CCCTGTCTC TATTTCTACT ATTTGGTGTT TGTCTGTAT TGTCTCTTC	4200
TTGTCTGGCT ATCATCACAA GAGCGGAACG GACTCACCAT AGGGACCAAG CTTGTGACA	4260
TCTAGGGCGG CCAATTCCGC CCCTCTCCCT CCCCCCCCC TAACGTACT GGCCGAAGCC	4320

GCTTGAATA AGGCCGGTGT GCGTTTGTCT ATATGTGATT TTCCACCATA TTGCCGTCTT	4380
TTGGCAATGT GAGGGCCCGG AAACCTGGCC CTGTCTTCTT GACGAGCATT CCTAGGGGTC	4440
TTTCCCCTCT CGCCAAAGGA ATGCAAGGTC TGTGAATGT CGTGAAGGAA GCAGTTCCTC	4500
TGAAGCTTC TTGAAGACAA ACAACGTCTG TAGCGACCCT TTGCAGGCAG CGGAACCCCC	4560
CACCTGGCGA CAGGTGCCTC TCGGGCCAAA AGCCACGTGT ATAAGATACA CCTGCAAAGG	4620
CGGCACAACC CCAGTGCCAC GTTGTGAGTT GGATAGTTGT GGAAAGAGTC AAATGGCTCT	4680
CCTCAAGCGT ATTCAACAAG GGGCTGAAGG ATGCCCAGAA GGTACCCCAT TGTATGGGAT	4740
CTGATCTGGG GCCTCGGTGC ACATGCTTTA CATGTGTTTA GTCGAGGTTA AAAAAACGTC	4800
TAGGCCCCC GAACCACGGG GACGTGGTTT TCCTTTGAAA AACACGCCAA TAATATGGGC	4860
GGCCGCTCGA GCATGCATCT AGAACATCGA TAAAATAAAA GATTTTATTT AGTCTCCAGA	4920
AAAAGGGGGG AATGAAAGAC CCCACCTGTA GGTTCGGCAA GCTAGCTTAA GTAACGCCAT	4980
TTTGCAAGGC ATGGAAAAAT ACATACTGA GAATAGAGAA GTTCAGATCA AGGTCAGGAA	5040
CAGATGGAAC AGCTGAATAT GGGCCAAACA GGATATCTGT GGTAAGCAGT TCCTGCCCCG	5100
GCTCAGGGCC AAGAACAGAT GGAACAGCTG AATATGGGCC AAACAGGATA TCTGTGGTAA	5160
GCAGTTCCTG CCCC GGCTCA GGGCCAAGAA CAGATGGTCC CCAGATGCGG TCCAGCCCTC	5220
AGCAGTTTCT AGAGAACCAT CAGATGTTTC CAGGGTGCCC CAAGGACCTG AAATGACCCT	5280
GTGCCTTATT TGAAC TAACC AATCAGTTCG CTTCTCGCTT CTGTTGCGGC GCTTCTGCTC	5340
CCCGAGCTCA ATAAAAGAGC CCACAACCCC TCACTCGGGG CGCCAGTCCT CCGATTGACT	5400
GAGTCGCCCC GGTACCCGTG TATCCAATAA ACCCTCTTGC AGTTGCATCC GACTTGTGGT	5460
CTCGCTGTTC CTTGGGAGGG TCTCCTCTGA GTGATTGACT ACCCGTCAGC GGGGGTCTTT	5520
CATTTGGGGG CTCGTCCGGG ATCGGGAGAC CCCTGCCCAG GGACCACCGA CCCACCACCG	5580
GGAGGTAAGC TGGCTGCCTC GCGCGTTTCG GTGATGACGG TGAAAACCTC TGACACATGC	5640
AGCTCCCGGA GACGGTCACA GCTTGTCTGT AAGCGGATGC CGGGAGCAGA CAAGCCCGTC	5700
AGGGCGCGTC AGCGGGTGTG GCGGGGTGTC GGGGCGCAGC CATGACCCAG TCACGTAGCG	5760
ATAGCGGAGT GTATACTGGC TTAAC TATGC GGCATCAGAG CAGATTGTAC TGAGAGTGCA	5820
CCATATGCGG TGTGAAATAC CGCACAGATG CGTAAGGAGA AAATACCGCA TCAGGCGCTC	5880
TTCCGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT CGGCTGCGGC GAGCGGTATC	5940
AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAATCA GGGGATAACG CAGGAAAGAA	6000

CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA AAGGCCGCGT TGCTGGCGTT	6060
TTTCCATAGG CTCCGCCCC CTGACGAGCA TCACAAAAT CGACGCTCAA GTCAGAGGTG	6120
GCGAAACCCG ACAGGACTAT AAAGATACCA GCGCTTTCCC CCTGGAAGCT CCCTCGTGCG	6180
CTCTCCTGTT CCGACCCTGC CGCTTACCGG ATACCTGTCC GCCTTTCTCC CTTGCGGAAG	6240
CGTGGCGCTT TCTCATAGCT CACGCTGTAG GTATCTCAGT TCGGTGTAGG TCGTTCGCTC	6300
CAAGCTGGGC TGTGTGCACG AACCCCCCGT TCAGCCCGAC CGCTGCGCCT TATCCGGTAA	6360
CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG CCACTGGCAG CAGCCACTGG	6420
TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA GAGTTCTTGA AGTGGTGGCC	6480
TAACACGGC TACACTAGAA GGACAGTATT TGGTATCTGC GCTCTGCTGA AGCCAGTTAC	6540
CTTCGGAAAA AGAGTTGGTA GCTCTTGATC CGGCAAAACA ACCACCGCTG GTAGCGGTGG	6600
TTTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG AAGATCCTTT	6660
GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAG GGATTTTGGT	6720
CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA AATTAAAAAT GAAGTTTTAA	6780
ATCAATCTAA AGTATATATG AGTAACTTG GTCTGACAGT TACCAATGCT TAATCAGTGA	6840
GGCACCTATC TCAGCGATCT GTCTATTTCTG TTCATCCATA GTTGCCCTGAC TCCCCGTCGT	6900
GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA TGATACCGCG	6960
AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC CAGCCAGCCG GAAGGGCCGA	7020
GCGCAGAAGT GGTCTGCAA CTTTATCCGC CTCCATCCAG TCTATTAATT GTTGCCGGGA	7080
AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTGCCA TTGCTGCAGG	7140
CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC AGCTCCGGTT CCCAACGATC	7200
AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAGCG GTTAGCTCCT TCGGTCCTCC	7260
GATCGTTGTC AGAAGTAAGT TGGCCGAGT GTTATCACTC ATGGTTATGG CAGCACTGCA	7320
TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTTCT GTGACTGGTG AGTACTCAAC	7380
CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCGG CGTCAACACG	7440
GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGA AACGTTCTTC	7500
GGGGCGAAAA CTCTCAAGGA TCTTACCCT GTTGAGATCC AGTTGATGT AACCCACTCG	7560
TGCACCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC GTTTCTGGGT GAGCAAAAAC	7620
AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT GAATACTCAT	7680

ACTCTTCCTT TTCAATATT ATTGAAGCAT TTATCAGGGT TATTGTCTCA TGAGCGGATA	7740
CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT TTCCCCGAAA	7800
AGTGCCACCT GACGTCTAAG AAACCATTAT TATCATGACA TTAACCTATA AAAATAGGCG	7860
TATCACGAGG CCCTTTCGTC TTCAA	7885

**THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:**

- 1) A method of producing a trans-somatic mammal, wherein said method provides the incorporation of a DNA sequence into the secretory cells of the mammary gland to alter the composition of the milk, wherein said method comprising the steps of:
 - a) providing a vector containing a DNA sequence encoding a valuable compound;
 - b) packaging said vector into a cell line;
 - c) preparing a solution comprising the packaged vector and cell line producing said packaged vector; and
 - d) delivering said solution into the mammary gland to allow the incorporation of the DNA into the secretory cells of the mammary gland.
- 2) The method of Claim 1, wherein the method further comprises the step of flushing the mammary gland with an osmotically-balanced solution prior to delivering the said solution into the mammary gland.
- 3) The method of Claim 2, wherein the method further comprises the step of externally massaging the mammary gland several times a day after delivering the said solution into the mammary gland.
- 4) The method of Claim 2, wherein the method further comprises the step of growing the cells producing said packaged vector on a solid support means, and the solution comprises the cells on said support means and the packaged vector.
- 5) The method of Claim 4, wherein the method further comprises the step of externally massaging the mammary gland several times a day after delivering the said solution into the mammary gland.
- 6) The method of Claim 2 or 4, wherein a substance, with a density higher than the density

of the solution, is delivered into the mammary gland after the delivery of the solution, wherein said substance displaces the solution upwards in the mammary gland.

- 7) The method of Claim 1, wherein the valuable compound is a pharmaceutical.
- 8) The method of Claim 7, wherein the pharmaceutical is a compound selected from the group consisting of: a tissue plasminogen activator, an antibody, an antibiotic, a blood clotting factor, galactosyltransferase, a growth factor, an oncoprotein, a hormone, a milk protein, a hormone receptor, a tumor suppressor protein, a vaccine and an erythropoietin.
- 9) The method of Claim 8, wherein the pharmaceutical is a tissue plasminogen activator.
- 10) The method of Claim 1, wherein the vector is transiently transfected into PA317 cells; the resulting particles are harvested and trans-infected into PG13 cells.
- 11) The method of Claim 1, wherein the vector is selected from the group pL(X)SH, pL(X)SN, pLNS(X), pLHS(X), pLNC(X), pLHC(X), pLNA(X) and pLHA(X); wherein "A" is the beta actin promoter, "L" is the moloney murine virus long terminal repeat (LTR), "S" is the SV40 promoter, "C" is the cytomegalovirus promoter and "X" is a DNA sequence encoding a valuable compound.
- 12) The method of Claim 1, wherein the vector is selected from the group consisting of pL(X)iN and pL(X)iH; wherein "I" is an internal ribosomal entry site (IRES) and "X" is a DNA sequence encoding a valuable compound.
- 13) The method of Claim 1, wherein the vector is pLNM(X); wherein "M" is a mouse mammary tumor virus promoter and "X" is a DNA sequence encoding a valuable compound.
- 14) The method of Claim 1, wherein the vector is pLNM_i₂(X); wherein "M" is a mouse mammary tumor virus promoter, "i₂" is a modified wild type internal ribosomal entry site and "X" is a DNA sequence encoding a valuable compound.

- 15) The method of Claims 11 to 14, wherein "X" is a DNA sequence encoding a tissue plasminogen activator.
- 16) The method of Claim 1, wherein the solution is an aqueous solution.
- 17) The method of Claim 2, wherein the osmotically-balanced solution is a saline solution.
- 18) The method of Claim 4, wherein the solid support means is a matrix selected from the group consisting of Cytodex beads or Cultisphere.
- 19) The method of Claim 6, wherein said substance is a silicone substance.
- 20) The method of Claim 1, wherein the vector is transfected into a packaging cell line producing a non-retroviral derived particle.
- 21) The method of Claim 1, wherein the vector is transfected into a packaging cell line producing a retroviral derived particle.
- 22) The method of Claim 1, wherein the trans-infecting particle is produced *in vitro*.
- 23) The method of Claim 1, wherein the trans-infecting particle is produced *in vivo*.




FIG. 1

2/2




FIG. 2

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/00607

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/00 A01K67/027 C12N15/86 C12N9/72		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A01K C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARCHER, J.S. ET AL.: "Human growth hormone (hGH) secretion in milk of goats after direct transfer of the hGH gene into the mammary gland by using replication-defective retrovirus vectors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 91, no. 15, 19 July 1994, pages 6840-6844, XP002088503 WASHINGTON US cited in the application	1,7-11
Y	see page 6844, column 1, line 12 - line 14 <div style="text-align: center;">--- -/-</div>	1-11
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">18 December 1998</div>		Date of mailing of the international search report <div style="text-align: center;">13/01/1999</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Chambonnet, F</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/00607

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>YANG, N.S. ET AL.: "Gene transfer into mammalian somatic cells in vivo"</p> <p>CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 12, no. 4, 1992, pages 335-356, XP002088504</p> <p>see page 338, column 2</p> <p>see page 341, paragraph 3.</p> <p>---</p>	1-11
A	<p>WO 96 22379 A (NEXIA BIOTECHNOLOGIES INC)</p> <p>25 July 1996</p> <p>see page 24, line 8 - line 11; claims</p> <p>---</p>	5,7-9,16
A	<p>US 5 215 904 A (GOULD & WANG) 1 June 1993</p> <p>cited in the application</p> <p>see the whole document</p> <p>---</p>	1
Y	<p>CULVER, K.W. ET AL.: "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors"</p> <p>SCIENCE., vol. 256, 12 June 1992, pages 1550-1552, XP002088505</p> <p>LANCASTER, PA US</p> <p>see the whole document</p> <p>---</p>	1-11
Y	<p>WO 95 15167 A (GENETIC THERAPY INC)</p> <p>8 June 1995</p> <p>see the whole document</p> <p>-----</p>	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/00607

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9622379 A	25-07-1996	US 5780009 A AU 4428496 A CA 2210897 A EP 0805869 A	14-07-1998 07-08-1996 25-07-1996 12-11-1997
US 5215904 A	01-06-1993	NONE	
WO 9515167 A	08-06-1995	CA 2177998 A EP 0735887 A JP 9507839 T	08-06-1995 09-10-1996 12-08-1997